Macrocyclic 2-amino-but-3-enamides as MCL-1 inhibitors
Macrocyclic 2-amino-but-3-enamide compounds serve as potent MCL-1 inhibitors, addressing the need for targeted cancer therapy by blocking MCL-1's pro-survival function in cancers with high MCL-1 expression.
Patent Information
- Application Number
- JP2024529112
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-16
- Filing Date
- 2022-11-15
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for effective MCL-1 inhibitors to treat or prevent various cancers, including prostate cancer, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, B-cell chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL), as these cancers often exhibit high MCL-1 expression leading to resistance to conventional therapies.
Development of macrocyclic 2-amino-but-3-enamide compounds that function as MCL-1 inhibitors, capable of binding to and inhibiting the pro-apoptotic effectors Bak and Bax or BH3-only sensitizers like Bim, Noxa, or Puma, thereby blocking MCL-1's pro-survival function.
The macrocyclic 2-amino-but-3-enamide compounds effectively inhibit MCL-1 activity, potentially enhancing apoptosis in cancer cells and providing a therapeutic approach for these cancers.
Smart Images

Figure 2024544570000001 
Figure 2024544570000002 
Figure 2024544570000003
Abstract
Description
[Technical field]
[0001] The present invention relates to medicaments useful for the treatment and / or prevention in a subject, pharmaceutical compositions comprising such compounds, and their use as MCL-1 inhibitors useful for the treatment or prevention of diseases such as cancer. [Background technology]
[0002] Cell apoptosis, or programmed cell death, is crucial for the development and homeostasis of many organs, including the hematopoietic system. Apoptosis can be initiated via the extrinsic pathway mediated by death receptors, or by the intrinsic pathway using the B-cell lymphoma (BCL-2) family of proteins. Myeloid cell leukemia-1 (MCL-1) is a member of the BCL-2 family of cell survival regulators and is a crucial mediator of the intrinsic apoptosis pathway. MCL-1 is one of five major anti-apoptotic BCL-2 proteins (MCL-1, BCL-2, BCL-XL, BCL-w, and BFL1 / A1) responsible for maintaining cell survival. MCL-1 sequentially and directly inhibits the activity of the pro-apoptotic BCL-2 family proteins Bak and Bax, and indirectly blocks apoptosis by sequestering BH3-only apoptosis sensitizer proteins such as Bim and Noxa. After various types of cellular stress, activation of Bak / Bax leads to their aggregation on the outer mitochondrial membrane, which promotes pore formation, loss of mitochondrial outer membrane potential, and subsequent release of cytochrome C into the cytosol. Cytosolic cytochrome C binds to Apaf-1 and initiates the recruitment of procaspase 9 to form the apoptosome structure (Cheng et al. eLife 2016;5:e17755). The assembly of the apoptosome activates the executioner cysteine proteases 3 / 7, and these effector caspases then cleave various cytoplasmic and nuclear proteins to induce cell death (Julian et al. Cell Death and Differentiation 2017;24,1380-1389).
[0003] Evasion of apoptosis is a well-established hallmark of cancer development, promoting the survival of tumor cells that would otherwise be eliminated due to oncogenic stress, growth factor deprivation, or DNA damage (Hanahan and Weinberg. Cell 2011;1-44). Not surprisingly, therefore, MCL-1 is highly upregulated in many solid and hematological cancers compared to normal non-transformed tissue counterparts. Overexpression of MCL-1 has been implicated in the pathogenesis of several cancers that correlate with poor outcome, recurrence, and aggressive disease. Moreover, overexpression of MCL-1 has been implicated in the pathogenesis of cancers such as prostate cancer, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, B-cell chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). The human MCL-1 locus (1q21) is frequently amplified in tumors, quantitatively increasing total MCL-1 protein levels (Beroukhim et al. Nature 2010;463(7283)899-905). MCL-1 also mediates resistance to conventional cancer therapeutics and is transcriptionally upregulated in response to inhibition of BCL-2 function (Yecies et al. Blood 2010;115(16)3304-3313).
[0004] Small molecule BH3 inhibitors of BCL-2 have shown clinical efficacy in patients with chronic lymphocytic leukemia and are FDA approved for patients with CLL or AML (Roberts et al. NEJM 2016;374:311-322). The clinical success of BCL-2 antagonism has led to the development of several MCL-1 BH3 mimetics that show efficacy in preclinical models of both hematological malignancies and solid tumors (Kotschy et al. Nature 2016;538 477-486, Merino et al. Sci. Transl. Med;2017(9)).
[0005] MCL-1 regulates several cellular processes in addition to its canonical role in mediating mitochondrial integrity and cell survival including non-homologous end joining after DNA damage (Chen et al. JCI 2018;128(1):500-516). Genetic loss of MCL-1 displays a range of phenotypes depending on developmental timing and tissue deletion. MCL-1 knockout models reveal that MCL-1 has multiple roles and loss of function affects a wide range of phenotypes. Global MCL-1-deficient mice exhibit embryonic lethality and studies using conditional gene deletion report mitochondrial dysfunction, impaired activation of autophagy, reduced B and T lymphocytes, increased B and T cell apoptosis, and development of heart failure / cardiomyopathy (Wang et al. Genes and Dev 2013;27 1351-1364, Steimer et al. Blood 2009;(113)2805-2815).
[0006] WO2019046150 discloses macrocyclic compounds that inhibit the mcl-1 protein.
[0007] WO2016033486 discloses tetrahydronaphthalene derivatives that inhibit the mcl-1 protein.
[0008] WO 2019036575, WO 2017147410, and WO 2018183418 disclose compounds that inhibit the mcl-1 protein.
[0009] WO2019222112 discloses MCL-1 inhibitors for treating cancer.
[0010] WO2020097577 discloses spirosulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein.
[0011] WO2021021259 describes formulations and dosages for administering compounds that inhibit the MCL1 protein.
[0012] WO2019173181 discloses MCL-1 inhibitors.
[0013] WO2021211922 discloses spirosulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein. Summary of the Invention
[0014] There remains a need for MCL-1 inhibitors that are useful for the treatment or prevention of cancers such as prostate cancer, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, B-cell chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
[0015] The present invention relates to a compound of formula (I):
[0016] [ka] [In the formula, R 1a and R 1b are each independently hydrogen, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, C 3~7 Cycloalkenyl, Het 1 , Ar 1 , Het 2 , and Cy 1 wherein the C is selected from the group consisting of 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, or C 3~7 Cycloalkenyl optionally has one or two R 2 is replaced by or R 1aand R 1b together with the N atom to which it is attached form a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, the S atom being optionally substituted to form S(=O) or S(=O)2, and the heterocyclyl is optionally selected from each independently selected from oxo, OR f , S.R. f , N.R. d R e , CN, Halo, CF3, and optionally, OR f , S.R. f C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 or substituted with 1 or 2 substituents selected from the group consisting of alkyl, or R 1a and R 1b together with the N atom to which it is attached form a 6-11 membered bicyclic fully saturated heterocyclyl containing one N atom and optionally one or two additional heteroatoms, each independently selected from O, S, and N, which S atom may be substituted to form S(=O) or S(=O)2, and which heterocyclyl is optionally selected from, each independently, oxo, OR f , S.R. f , N.R. d R e , CN, Halo, CF3, and optionally, OR f , S.R. f C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Each R 2 OR f , S.R. f , CN, Halo, CF3, NR m R n , SO2R c , C(=O)R c , C(=O)OR d , C(=O)NR d R e , SO2NR d R e , C3~7 Cycloalkyl, C 3~7 Cycloalkenyl, Het 1 , Ar 1 , Het 2 , and Cy 1 are independently selected from the group consisting of C 3~7 Cycloalkyl or C 3~7 Cycloalkenyl is optionally represented by OR f , S.R. f , CN, Halo, and NR d R e and is substituted with one or two substituents each independently selected from the group consisting of: R c is C 1~6 Alkyl, C 3~7 Cycloalkyl, Het 1 , Ar 1 , and Het 2 is selected from the group consisting of R m and R n are each independently hydrogen, methyl, or C 2~7 Alkyl, C 3~7 cycloalkyl, Het1, Ar1, and Het2, 2~7 Alkyl or C 3~7 Cycloalkyl is optionally selected from the group consisting of OR i , S.R. i , N.R. g R h , CN, Halo, and optionally, OR i , S.R. i , C.N., N.R. g R h and C substituted with one substituent selected from the group consisting of halo 1~4 or substituted with 1 or 2 substituents selected from the group consisting of alkyl, R d and R e are each independently hydrogen, methyl, or C 2~7 Alkyl, C 3~7 Cycloalkyl, Het 1 , Ar 1 , and Het 2wherein the C is selected from the group consisting of 2~7 Alkyl or C 3~7 Cycloalkyl is optionally selected from the group consisting of OR i , S.R. i , N.R. g R h , CN, Halo, and optionally, OR i , S.R. i , C.N., N.R. g R h and C substituted with one substituent selected from the group consisting of halo 1~4 or substituted with 1 or 2 substituents selected from the group consisting of alkyl, or R d and R e together with the N atom to which it is attached form a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, the S atom being optionally substituted to form S(=O) or S(=O)2, the heterocyclyl being optionally each independently selected from OR i , S.R. i , N.R. g R h , CN, Halo, CF3, and optionally, OR i , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 or substituted with 1 or 2 substituents selected from the group consisting of alkyl, or R d and R e together with the N atom to which it is attached form a fused 6-11 membered bicyclic fully saturated heterocyclyl containing one N atom and optionally one or two additional heteroatoms, each independently selected from O, S, and N, which S atom may be substituted to form S(=O) or S(=O)2, and which heterocyclyl is optionally selected from OR i , S.R. i , N.R. g R h , CN, Halo, CF3, and optionally, OR i , S.R.i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; n is 1 or 2; R f is hydrogen, C 1~6 Alkyl, CF3, C 3~7 Cycloalkyl, Het 1 , Ar 1 , Het 2 wherein the C is selected from the group consisting of 1~6 Alkyl or C 3~7 Cycloalkyl is optionally represented by OR i , S.R. i ,CN,Haro,NR m R n , SO2R c , C(=O)R c , C(=O)OR d , C(=O)NR d R e , SO2NR d R e , C 3~7 Cycloalkyl, Het 1 , Ar 1 and Het 2 and is substituted with one substituent selected from the group consisting of R g and R h are each independently hydrogen, C 1~6 Alkyl, and C 3~7 cycloalkyl; or R g and R h together with the N atom to which it is attached, forms a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, the S atom being optionally substituted to form S(=O) or S(=O)2; Het 1each independently represent a 4- to 7-membered monocyclic fully saturated heterocyclyl containing 1 or 2 heteroatoms selected from O, S, and N, the S atom may be substituted to form S(=O) or S(=O)2, and the heterocyclyl may optionally be selected from the group consisting of OR i , S.R. i , N.R. j R k , CN, Halo, CF3, and optionally, OR i , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Het 2 each independently represent a 5-6 membered monocyclic aromatic ring containing 1, 2, 3, or 4 heteroatoms selected from O, S, and N, the S atom may be substituted to form S(=O) or S(=O)2, and the aromatic ring may optionally be each independently represented by OR i , S.R. i , N.R. j R k , CN, Halo, CF3, and optionally, OR i , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Cy 1 represents a 6-11 membered bicyclic fully saturated ring system optionally containing 1 or 2 heteroatoms each independently selected from O, S, and N, the S atom may be substituted to form S(=O) or S(=O)2, the ring system optionally being represented by the following radicals each independently: OR i , S.R. i , N.R. j R k , CN, Halo, CF3, and optionally, OR i , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Ar 1 are optional and each independently: OR i , S.R. i , N.R. g R h , CN, Halo, CF3, and optionally, OR i , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 represents a phenyl substituted by one or two substituents selected from the group consisting of alkyl, R i is hydrogen, C 1~6 Alkyl or C 3~7 represents cycloalkyl, R j and R k are each independently hydrogen, C 1~6 Alkyl, and C 3~7 cycloalkyl; R 3 is hydrogen, C 1~4 Alkyl or C 1~4 represents alkyl-OH, R 4 represents hydrogen or methyl; R 5 -(C=O)-phenyl, -(C=O)-Het 4 or -(C=O)-Het 3 The phenyl, Het 3 , or Het 4 is optionally substituted with 1 or 2 substituents selected from methyl or methoxy; Het 4 each independently represents a C-bonded 4- to 7-membered monocyclic fully saturated heterocyclyl containing 1 or 2 heteroatoms selected from O, S, and N, the S atom may be substituted to form S(=O) or S(=O)2, Het 3 represents a C-bonded 5- or 6-membered monocyclic aromatic ring containing 1, 2, or 3 heteroatoms each independently selected from O, S, and N; Y represents O or CH2; X 1 CR6 represents X 2 CR 7 represents X 3 CR 8 represents R 6 , R 7 , and R 8 each independently represents hydrogen, fluoro, or chloro; X 4 is O or NR 5 represents] and pharma- ceutically acceptable salts and solvates thereof.
[0017] The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), a pharma- ceutically acceptable salt thereof, or a pharma- ceutically acceptable solvate thereof, and a pharma- ceutically acceptable carrier or excipient.
[0018] Furthermore, the present invention relates to a compound of formula (I), a pharma- ceutically acceptable salt or solvate thereof, for use as a medicament, and also to a compound of formula (I), a pharma- ceutically acceptable salt or solvate thereof, for use in the treatment or prevention of cancer.
[0019] In a particular embodiment, the present invention relates to a compound of formula (I), a pharma- ceutically acceptable salt, or a pharma- ceutically acceptable solvate thereof, for use in the treatment or prevention of cancer.
[0020] The present invention also relates to the use of a compound of formula (I), a pharma- ceutically acceptable salt or solvate thereof, in combination with an additional pharmaceutical agent, for use in the treatment or prevention of cancer.
[0021] The present invention further relates to a process for preparing a pharmaceutical composition according to the present invention, characterized in that a pharma- ceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound of formula (I), a pharma- ceutically acceptable salt or solvate thereof.
[0022] The present invention also relates to a product comprising a compound of formula (I), a pharma- ceutically acceptable salt or solvate thereof, and an additional pharmaceutical agent as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of cancer.
[0023] Furthermore, the present invention relates to a method for treating or preventing a cell proliferative disorder in a subject, comprising administering to said subject an effective amount of a compound of formula (I), a pharma- ceutically acceptable salt or solvate thereof, as defined herein, or a pharmaceutical composition or combination, as defined herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] As used herein, the term "halo" or "halogen" refers to fluoro, chloro, bromo, and iodo.
[0025] As used herein, the prefix "C x~y " (where x and y are integers) refers to the number of carbon atoms in a given group. Thus, C 1~6 An alkyl group contains 1 to 6 carbon atoms, and so on.
[0026] As used herein as a group or part of a group, "C 1~4 The term "alkyl" refers to a straight or branched chain fully saturated hydrocarbon radical having from 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl, and the like.
[0027] As used herein as a group or part of a group, "C 1~6 The term "alkyl" refers to a straight or branched chain fully saturated hydrocarbon radical having from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl, n-pentyl, n-hexyl, and the like.
[0028] As used herein as a group or part of a group, "C 2~7The term "alkyl" refers to a straight or branched chain fully saturated hydrocarbon radical having from 2 to 7 carbon atoms, such as ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl, n-pentyl, n-hexyl, and the like.
[0029] As used herein as a group or part of a group, "C 3~7 The term "cycloalkyl" defines a fully saturated cyclic hydrocarbon radical having from 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0030] As used herein as a group or part of a group, "C 2~6 The term "alkenyl" refers to a double bond containing straight or branched chain hydrocarbon radical having from 2 to 6 carbon atoms, such as ethenyl, propenyl, isopropenyl, buten-1-yl, (2Z)-buten-2-yl, (2E)-buten-2-yl, buten-3-yl, 2-methylpropen-1-yl, 1,3-butadiene, penten-1-yl, (2Z)-penten-2-yl, (2E)-penten-2-yl, (3Z)-penten-3-yl, (3E)-penten-3-yl, (4Z)-penten-4-yl, (4E)-penten-4-yl, penten-5-yl, and the like.
[0031] As used herein as a group or part of a group, "C 3~7 The term "cycloalkyl" defines a double bond containing cyclic hydrocarbon radical having from 3 to 7 carbon atoms, such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and cycloheptenyl.
[0032] As used herein as a group or part of a group, "C 2~6 The term "alkynyl" refers to a triple bond containing straight or branched chain hydrocarbon radical having from 2 to 6 carbon atoms, such as ethynyl, 1-propynyl, 2-propynyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, 1,3-butadiyn, pentyn-1-yl, pentyn-2-yl, pentyn-3-yl, pentyn-5-yl, and the like.
[0033] It will be apparent to those skilled in the art that S(=O)2 or SO2 represents a sulfonyl moiety.
[0034] It will be apparent to one skilled in the art that CO or C(=O) represent a carbonyl moiety.
[0035] Non-limiting examples of two R groups that, together with the N atom to which they are attached, form a 4- to 7-membered monocyclic fully saturated heterocyclyl containing one N atom and, optionally, one additional heteroatom selected from O, S, and N, include, but are not limited to, N-linked azetidinyl, N-linked pyrrolidinyl, N-linked morpholinyl, N-linked piperazinyl, and N-linked piperidinyl.
[0036] Non-limiting examples of 4- to 7-membered monocyclic fully saturated heterocyclyls containing 1 or 2 heteroatoms, each independently selected from O, S, and N, include, but are not limited to, tetrahydropyranyl, piperazinyl, tetrahydrofuranyl, 1,4-dioxanyl, tetrahydropyranyl, 1,4-oxazepanyl, 1,3-dioxolanyl, morpholinyl, and azetidinyl.
[0037] Non-limiting examples of C-linked 4- to 7-membered monocyclic fully saturated heterocyclyls containing 1 or 2 heteroatoms, each independently selected from O, S, and N, include, but are not limited to, C-linked tetrahydropyranyl, C-linked piperazinyl, C-linked tetrahydrofuranyl, C-linked 1,4-dioxanyl, C-linked tetrahydropyranyl, C-linked 1,4-oxazepanyl, C-linked 1,3-dioxolanyl, C-linked morpholinyl, and C-linked azetidinyl.
[0038] In the context of this invention a bicyclic 6- to 11-membered bicyclic fully saturated heterocyclyl group, or a 6- to 11-membered bicyclic fully saturated ring system, includes fused, spiro and bridged bicyclic systems.
[0039] A fused bicyclic group is two rings which share two atoms and a bond between those atoms.
[0040] A spiro bicyclic group has two rings joined at a single atom.
[0041] A bridged bicyclic group has two rings which have three or more atoms in common.
[0042] Examples of 6-11 membered bicyclic fully saturated ring systems optionally containing 1 or 2 heteroatoms each independently selected from O, S, and N include:
[0043] [ka] These include, but are not limited to, the following.
[0044] Examples of two R groups that, together with the N atom to which they are attached, form a 6-11 membered bicyclic fully saturated heterocyclyl containing one N atom and optionally one or two additional heteroatoms, each independently selected from O, S, and N, include:
[0045] [ka] These include, but are not limited to, the following.
[0046] Non-limiting examples of 5-6 membered monocyclic aromatic rings containing 1 or 2 heteroatoms, each independently selected from O, S, and N, include:
[0047] [ka] These include, but are not limited to, the following.
[0048] Non-limiting examples of C-linked 5-6 membered monocyclic aromatic rings containing 1 or 2 heteroatoms each independently selected from O, S, and N include:
[0049] [ka] These include, but are not limited to, the following.
[0050] Unless otherwise stated or apparent from the context, heterocyclyl groups (e.g., Het 1 ), aromatic rings containing heteroatoms (e.g., Het 2 ), or a ring system containing a heteroatom (e.g., Cy 1 ) may be attached to the remainder of the molecule of formula (I) by any available ring carbon atom (C-bond) or nitrogen atom (N-bond), if available.
[0051] In general, whenever the term "substituted" is used in this invention, unless otherwise indicated or apparent from the context, it is meant to indicate that one or more hydrogens, particularly 1 to 4 hydrogens, more particularly 1 to 3 hydrogens, preferably 1 or 2 hydrogens, more preferably 1 hydrogen, on the atom or radical shown in the expression are replaced with a selection from the group shown, provided that the normal valences are not exceeded, and that the replacement results in a chemically stable compound, i.e., a compound that is sufficiently robust to survive isolation to a useful purity from a reaction mixture.
[0052] Combinations of substituents and / or variables are permissible only if such combinations result in chemically stable compounds. "Stable compound" is meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture.
[0053] Those of skill in the art will understand that the term "optionally substituted" means that the atom or radical designated in the expression using "optionally substituted" may be substituted or unsubstituted (which means substituted or unsubstituted, respectively).
[0054] When two or more substituents are present on a moiety, they may replace hydrogen atoms on the same atom or they may replace hydrogen atoms on different atoms in the moiety, unless otherwise stated or apparent from the context.
[0055] When any variable occurs more than one time in any constituent, each definition is independent.
[0056] As used herein, the term "subject" refers to an animal, preferably a mammal (e.g., a cat, dog, primate, or human), more preferably a human, who is or has been the object of treatment, observation, or experiment.
[0057] As used herein, the term "therapeutically effective amount" means an amount of an active compound or pharmaceutical agent that produces the biological response or beneficial effect in a tissue system or subject (e.g., a human) that is desired by a researcher, veterinarian, physician, or other clinician, including alleviation or reversal of the symptoms of the disease or disorder being treated.
[0058] The term "composition" is intended to encompass a product comprising specified ingredients in specified amounts, and any product that results directly or indirectly from a combination of the specified ingredients in the specified amounts.
[0059] As used herein, the term "treatment" is intended to refer to any process that can slow, hinder, inhibit, or halt the progression of a disease, although it does not necessarily indicate the complete disappearance of all symptoms.
[0060] As used herein, the term "compounds of the invention" or "compounds according to the invention" is meant to include compounds of formula (I) and their pharma- ceutically acceptable salts and solvates.
[0061] As used herein, any chemical formula with bonds shown only as solid lines and not as solid wedge bonds or hashed wedge bonds, or otherwise shown as having a particular configuration (e.g., R, S) around one or more atoms, contemplates each possible stereoisomer, or a mixture of two or more stereoisomers. If the stereochemistry of any particular chiral atom is not specified in the structures shown herein, then all stereoisomers are contemplated and included as compounds of the invention, either as pure stereoisomers or as mixtures of two or more stereoisomers.
[0062] Above and below, the term "compounds of formula (I)" is intended to include its stereoisomers and its tautomers. However, as noted in the previous paragraph, where stereochemistry is designated by bonds shown as solid wedge bonds or hashed wedge bonds or otherwise shown as having a particular configuration (e.g., R, S), or where stereochemistry around a double bond is shown (e.g., in formula (I)), then the stereoisomers are so designated and defined. It will be apparent that this also applies to subgroups of formula (I).
[0063] It follows that a single compound may exist in both stereoisomers and tautomers, where possible.
[0064] Above and below, the terms "stereoisomer", "stereoisomeric form" or "stereochemically isomeric form" are used interchangeably.
[0065] The present invention includes all stereoisomers of the compounds of the present invention, either as a pure stereoisomer or as a mixture of two or more stereoisomers.
[0066] Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.
[0067] Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, i.e., they are not related as mirror images. When a compound contains a double bond, the substituents may be in the E or Z configuration.
[0068] Substituents on a divalent cyclic saturated or partially saturated radical can have either the cis or trans configuration; for example, if the compound contains a disubstituted cycloalkyl group, the substituents can be in either the cis or trans configuration.
[0069] Thus, the present invention includes enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers, and mixtures thereof, unless the context indicates otherwise and whenever chemically possible.
[0070] The meanings of all terms, i.e. enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, are known to the person skilled in the art.
[0071] Absolute configuration is specified according to the Cahn-Ingold-Prelog system. The configuration at the asymmetric atom is specified by either R or S. Resolved stereoisomers whose absolute configuration is not known can be designated (+) or (-) depending on the direction they rotate plane polarized light. For example, resolved enantiomers whose absolute configuration is not known can be designated (+) or (-) depending on the direction they rotate plane polarized light.
[0072] When a particular stereoisomer is specified, this means that the stereoisomer is substantially free of other stereoisomers, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, particularly less than 2%, and most preferably less than 1% of other stereoisomers. Thus, when a compound of formula (I) is specified, for example, as (R), this means that the compound is substantially free of the (S) isomer, when a compound of formula (I) is specified, for example, as E, this means that the compound is substantially free of the Z isomer, and when a compound of formula (I) is specified, for example, as cis, this means that the compound is substantially free of the trans isomer.
[0073] Pharmaceutically acceptable salts, particularly pharma-ceutically acceptable addition salts, include acid addition salts and base addition salts.Such salts can be formed by conventional means, for example, by reacting a free acid form or a free base form with one or more equivalents of a suitable base or acid, optionally in a solvent or in a medium in which the salt is insoluble, and then removing the solvent or medium using standard techniques (for example, in vacuum, by lyophilization, or by filtration).Salts can also be prepared by exchanging the counterion of the compound of the present disclosure in the form of a salt with another counterion, for example, by using a suitable ion exchange resin.
[0074] The pharma- ceutically acceptable salts referred to above and below are intended to include the therapeutically active non-toxic acid and base salt forms which the compounds of formula (I) and their solvates are able to form.
[0075] Suitable acids include, for example, inorganic acids such as hydrohalic acids, e.g., hydrochloric or hydrobromic acids, sulfuric, nitric, phosphoric acids, and the like; or organic acids such as, for example, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, oxalic acid (i.e., ethanedioic acid), malonic acid, succinic acid (i.e., butanedioic acid), maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclamic acid, salicylic acid, p-aminosalicylic acid, pamoic acid, and the like. Conversely, the salt forms can be converted to the free base forms by treatment with an appropriate base.
[0076] The compounds of formula (I) or solvates thereof containing acidic protons may be converted into their non-toxic metal or amine salt forms by treatment with appropriate organic and inorganic bases.
[0077] Suitable base salt forms include, for example, ammonium salts, alkali and alkaline earth metal salts such as lithium, sodium, potassium, cesium, magnesium, calcium salts, and the like, organic bases such as primary, secondary and tertiary aliphatic amines and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline, and isoquinoline; benzathine, N-methyl-glucamine, hydrabamine salts, and salts with amino acids such as arginine, lysine, and the like. Conversely, the base forms can be converted to the free base forms by treatment with acid.
[0078] The term solvates comprises the solvent addition forms, which the compounds of formula (I) are able to form, as well as the salts thereof. Examples of such solvent addition forms are, for example, hydrates, alcoholates, etc.
[0079] The compounds of the present invention prepared by the process described below may be synthesized in the form of a mixture of enantiomers, in particular a racemic mixture of enantiomers, which can be separated from each other according to resolution procedures known in the art. Methods for separating the enantiomeric forms of the compounds of formula (I) and its pharma-ceutically acceptable salts, N-oxides, and solvates include liquid chromatography using chiral stationary phases. Said pure stereochemically isomers may also be derived from the corresponding pure stereochemically isomers of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably, when a specific stereoisomer is desired, said compound will be synthesized by stereospecific preparation methods. These methods will advantageously employ enantiomerically pure starting materials.
[0080] As used herein, the term "enantiomerically pure" means that the product contains at least 80% by weight of one enantiomer and no more than 20% by weight of the other enantiomer. Preferably, the product contains at least 90% by weight of one enantiomer and no more than 10% by weight of the other enantiomer. In the most preferred embodiment, the term "enantiomerically pure" means that the composition contains at least 99% by weight of one enantiomer and no more than 1% of the other enantiomer.
[0081] The present invention also encompasses isotopically labeled compounds of the present invention that are identical to those enumerated herein, but by virtue of the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature (or the most abundant atom found in nature).
[0082] All isotopes and isotopic mixtures of any particular atom or element identified herein, whether naturally occurring or synthetically produced, either at natural abundance or in isotopically enriched form, are contemplated within the scope of the compounds of the invention. Exemplary isotopes that can be incorporated into the compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine;2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 O. 17 O. 18 O. 32 P, 33 P, 35 S, 18 F, 36 Cl, 122 I, 123 I, 125 I, 131 I, 75 Br, 76 Br, 77 Br, and 82 Br, etc. Preferably, the isotope is 2 H, 3 H, 11 C, and 18 F. More preferably, the isotope is selected from the group 2 H. Deuterated compounds are specifically intended to be included within the scope of the present invention.
[0083] Certain isotopically labeled compounds of the present invention (e.g., 3 H and 14 C) can be useful, for example, in substrate tissue distribution assays. 3 H) and carbon-l4( 14 C) isotopes are useful for their ease of preparation and detectability. Additionally, heavier isotopes, such as deuterium (i.e., 2 Substitution with, for example, H, may result in greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and therefore may confer certain therapeutic advantages and therefore may be preferred in some circumstances. For example, 15 O. 13 N, 11 C, and 18Positron-emitting isotopes such as F are useful in positron emission tomography (PET) studies. PET imaging in cancer finds utility in helping to localize and identify tumors, stage disease, and determine suitable treatments. Human cancer cells overexpress many receptors or proteins that are potential disease-specific molecular targets. Radiolabeled tracers that bind with high affinity and specificity to such receptors or proteins on tumor cells have great potential for diagnostic imaging and targeted radionuclide therapy (Charron, Carlie L. et al. Tetrahedron Lett. 2016, 57(37), 4119-4127). Furthermore, target-specific PET radiotracers can be used as biomarkers to investigate and evaluate pathology, for example, by measuring target expression and treatment response (Austin R. et al. Cancer Letters (2016), doi:10.1016 / j.canlet.2016.05.008).
[0084] In one embodiment, the present invention provides a method for the preparation of a compound represented by formula (I): [In the formula, R 1a and R 1b are each independently hydrogen, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, C 3~7 Cycloalkenyl, Het 1 , Ar 1 , Het 2 , and Cy 1 is selected from the group consisting of C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, or C 3~7 Cycloalkenyl optionally has one or two R 2 or or R 1a and R 1btogether with the N atom to which it is attached form a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, the S atom being optionally substituted to form S(=O) or S(=O)2, and the heterocyclyl is optionally selected from each independently selected from oxo, OR f , S.R. f , N.R. d R e , CN, Halo, CF3, and optionally, OR f , S.R. f C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 or substituted with 1 or 2 substituents selected from the group consisting of alkyl, or R 1a and R 1b together with the N atom to which it is attached form a 6-11 membered bicyclic fully saturated heterocyclyl containing one N atom and optionally one or two additional heteroatoms, each independently selected from O, S, and N, which S atom may be substituted to form S(=O) or S(=O)2, and which heterocyclyl is optionally selected from, each independently, oxo, OR f , S.R. f , N.R. d R e , CN, Halo, CF3, and optionally, OR f , S.R. f C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Each R 2 OR f , S.R. f , CN, Halo, CF3, NR m R n , SO2R c , C(=O)R c , C(=O)OR d , C(=O)NR d R e , SO2NR d R e , C 3~7Cycloalkyl, C 3~7 Cycloalkenyl, Het 1 , Ar 1 , Het 2 , and Cy 1 are independently selected from the group consisting of C 3~7 Cycloalkyl or C 3~7 Cycloalkenyl is optionally represented by OR f , S.R. f , CN, Halo, and NR d R e and is substituted with one or two substituents each independently selected from the group consisting of: R c is C 1~6 Alkyl, C 3~7 Cycloalkyl, Het 1 , Ar 1 , and Het 2 is selected from the group consisting of R m and R n are each independently hydrogen, methyl, or C 2~7 Alkyl, C 3~7 Cycloalkyl, Het 1 , Ar 1 , and Het 2 wherein the C is selected from the group consisting of 2~7 Alkyl or C 3~7 Cycloalkyl is optionally selected from the group consisting of OR i , S.R. i , N.R. g R h , CN, Halo, and optionally, OR i , S.R. i , C.N., N.R. g R h and C substituted with one substituent selected from the group consisting of halo 1~4 or substituted with 1 or 2 substituents selected from the group consisting of alkyl, R d and R e are each independently hydrogen, methyl, or C 2~7 Alkyl, C 3~7 Cycloalkyl, Het 1 , Ar 1, and Het 2 wherein the C is selected from the group consisting of 2~7 Alkyl or C 3~7 Cycloalkyl is optionally selected from the group consisting of OR i , S.R. i , N.R. g R h , CN, Halo, and optionally, OR i , S.R. i , C.N., N.R. g R h and C substituted with one substituent selected from the group consisting of halo 1~4 or substituted with 1 or 2 substituents selected from the group consisting of alkyl, or R d and R e together with the N atom to which it is attached form a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, the S atom being optionally substituted to form S(=O) or S(=O)2, the heterocyclyl being optionally each independently selected from OR i , S.R. i , N.R. g R h , CN, Halo, CF3, and optionally, OR i , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 or substituted with 1 or 2 substituents selected from the group consisting of alkyl, or R d and R e together with the N atom to which it is attached form a fused 6-11 membered bicyclic fully saturated heterocyclyl containing one N atom and optionally one or two additional heteroatoms, each independently selected from O, S, and N, which S atom may be substituted to form S(=O) or S(=O)2, and which heterocyclyl is optionally selected from OR i , S.R. i , N.R. g R h , CN, Halo, CF3, and optionally, ORi , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; n is 1 or 2; R f is hydrogen, C 1~6 Alkyl, CF3, C 3~7 Cycloalkyl, Het 1 , Ar 1 , Het 2 wherein the C is selected from the group consisting of 1~6 Alkyl or C 3~7 Cycloalkyl is optionally represented by OR i , S.R. i ,CN,Haro,NR m R n , SO2R c , C(=O)R c , C(=O)OR d , C(=O)NR d R e , SO2NR d R e , C 3~7 Cycloalkyl, Het 1 , Ar 1 and Het 2 and is substituted with one substituent selected from the group consisting of R g and R h are each independently hydrogen, C 1~6 Alkyl, and C 3~7 cycloalkyl; or R g and R h together with the N atom to which it is attached, forms a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, the S atom being optionally substituted to form S(=O) or S(=O)2; Het 1each independently represent a 4- to 7-membered monocyclic fully saturated heterocyclyl containing 1 or 2 heteroatoms selected from O, S, and N, the S atom may be substituted to form S(=O) or S(=O)2, and the heterocyclyl may optionally be selected from the group consisting of OR i , S.R. i , N.R. j R k , CN, Halo, CF3, and optionally, OR i , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Het 2 each independently represent a 5-6 membered monocyclic aromatic ring containing 1, 2, 3, or 4 heteroatoms selected from O, S, and N, the S atom may be substituted to form S(=O) or S(=O)2, and the aromatic ring may optionally be each independently represented by OR i , S.R. i , N.R. j R k , CN, Halo, CF3, and optionally, OR i , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Cy 1 represents a 6-11 membered bicyclic fully saturated ring system optionally containing 1 or 2 heteroatoms each independently selected from O, S, and N, the S atom may be substituted to form S(=O) or S(=O)2, the ring system optionally being represented by the following radicals each independently: OR i , S.R. i , N.R. j R k , CN, Halo, CF3, and optionally, OR i , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Ar 1 are optional and each independently: OR i , S.R. i , N.R. g R h , CN, Halo, CF3, and optionally, OR i , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 represents a phenyl substituted by one or two substituents selected from the group consisting of alkyl, R i is hydrogen, C 1~6 Alkyl or C 3~7 represents cycloalkyl, R j and R k are each independently hydrogen, C 1~6 Alkyl, and C 3~7 cycloalkyl; R 3 is hydrogen, C 1~4 Alkyl or C 1~4 represents alkyl-OH, R 4 represents methyl, Y represents O or CH2; X 1 CR 6 represents X 2 CR 7 represents X 3 CR 8 represents R 6 , R 7 , and R 8 each independently represents hydrogen, fluoro, or chloro; X 4 represents O] The present invention relates to novel compounds of the formula:
[0085] In one embodiment, the present invention provides a method for the preparation of a compound represented by formula (I): [In the formula, R 1a and R 1b is one or two R2 Optionally replaced by C 1~6 represents an alkyl group, or R 1a and R 1b taken together with the N atom to which they are attached form a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, the S atom being substituted to form S(=O) or S(=O)2; Each R 2 OR f and Het 1 are independently selected from the group consisting of n is 1 or 2; R f is C 1~6 represents an alkyl group, Het 1 each independently represents a 4- to 7-membered monocyclic fully saturated heterocyclyl containing one or two heteroatoms selected from O, S, and N, and the S atom may be substituted to form S(=O) or S(=O)2; R 3 represents hydrogen, R 4 represents methyl, Y represents CH2; X 1 CR 6 represents X 2 CR 7 represents X 3 CR 8 represents R 6 , R 7 , and R 8 represents hydrogen, X 4 represents O] The present invention relates to novel compounds of the formula:
[0086] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R 1a represents methyl.
[0087] In certain embodiments, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and the pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Y represents O.
[0088] In certain embodiments, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and their pharma- ceutically acceptable salts and solvates, or any subgroup thereof, wherein Y represents CH2.
[0089] In certain embodiments, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein n is 1.
[0090] In certain embodiments, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein n is 2.
[0091] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R 1a is R 1b does not form a heterocyclyl together with
[0092] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R d is R edoes not form a heterocyclyl together with
[0093] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R 1a is R 1b Become one with me.
[0094] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R 1a and R 1b is taken together with the N atom to which it is attached to form a heterocyclyl, as defined in any of the other embodiments.
[0095] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R 1a and R 1b is taken together with the N atom to which it is attached to form a monocyclic heterocyclyl, as defined in any of the other embodiments.
[0096] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R 1a and R 1b is taken together with the N atom to which it is attached to form a bicyclic heterocyclyl, as defined in any of the other embodiments.
[0097] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1bare each independently Hydrogen, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, C 3~7 Cycloalkenyl, Het 1 , Ar 1 , Het 2 , and Cy 1 is selected from the group consisting of C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, or C 3~7 Cycloalkenyl optionally has one or two R 2 is replaced by.
[0098] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1b are each independently C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, C 3~7 Cycloalkenyl, Het 1 , Ar 1 , Het 2 , and Cy 1 is selected from the group consisting of C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, or C 3~7 Cycloalkenyl optionally has one or two R 2 is replaced by.
[0099] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1b are each independently C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl and C 3~7 cycloalkenyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, or C 3~7 Cycloalkenyl optionally has one or two R 2 is replaced by.
[0100] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1b are each independently Optionally, one R 2 C replaced with 1~6 alkyl.
[0101] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1b are each independently Het 1 , Ar 1 , and optionally one R 2 C replaced with 1~6 alkyl.
[0102] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1b are each independently Het 1 , Ar 1 , and optionally one R 2 C replaced with 1~6 is selected from the group consisting of alkyl, R 2 OR f , CF3, NR m R n , SO2R c , Het 1 , and Het 2 are independently selected from the group consisting of:
[0103] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1b are each independently Optionally, one R 2 C replaced with 1~6 is selected from the group consisting of alkyl, R 2 OR f and Het 1 is selected from the group consisting of:
[0104] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1b are each independently Optionally, one R 2 C replaced with 1~6 is selected from the group consisting of alkyl, R 2 OR f and Het 1 is selected from the group consisting of n is 2.
[0105] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1b is not hydrogen.
[0106] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1b together with the N atom to which it is attached form a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, the S atom being optionally substituted to form S(=O) or S(=O)2, the heterocyclyl being optionally each independently selected from oxo, OR f , S.R. f , N.R. d R e , CN, Halo, CF3, and optionally, OR f , S.R. f C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 and substituted with 1 or 2 substituents selected from the group consisting of alkyl.
[0107] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1btogether with the N atom to which it is attached form a 6-11 membered bicyclic fully saturated heterocyclyl containing one N atom and optionally one or two additional heteroatoms, each independently selected from O, S, and N, which S atom may be substituted to form S(=O) or S(=O)2, and which heterocyclyl is optionally selected from each independently selected from oxo, OR, f , S.R. f , N.R. d R e , CN, Halo, CF3, and optionally, OR f , S.R. f C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 and substituted with 1 or 2 substituents selected from the group consisting of alkyl.
[0108] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1b together with the N atom to which it is attached form a 4- to 7-membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, each heterocyclyl optionally independently being selected from OR f , N.R. d R e , CN, Halo, CF3, and optionally, OR f and C substituted with one substituent selected from the group consisting of CN 1~4 and substituted with 1 or 2 substituents selected from the group consisting of alkyl.
[0109] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 1a and R 1btogether with the N atom to which it is attached form a 6-11 membered bicyclic fully saturated heterocyclyl containing one N atom and optionally one or two additional heteroatoms, each independently selected from O, S, and N, which heterocyclyl optionally contains, each independently, halo and C 1~4 and substituted with 1 or 2 substituents selected from the group consisting of alkyl.
[0110] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein each R 2 are, independently, OR f , CF3, NR m R n , SO2R c , Het 1 , and Het 2 is selected from the group consisting of:
[0111] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 3 represents hydrogen, R 4 represents methyl, and X 4 represents O.
[0112] In certain embodiments, the present invention relates to those compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein: R 4 represents methyl, and X 4 represents O.
[0113] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein X 4 represents O.
[0114] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein X 4 is NR 5 Represents.
[0115] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R 6 , R 7 , and R 8 each independently represents hydrogen or fluoro.
[0116] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R 6 , R 7 , and R 8 represents hydrogen.
[0117] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R 6 , R 7 , and R 8 represents fluoro.
[0118] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Het 1 is attached to the remainder of the molecule of formula (I) by any available ring carbon atom.
[0119] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Het 1 is attached to the remainder of the molecule of formula (I) by any available ring nitrogen atom.
[0120] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Het 1 teeth, each optionally substituted according to any one of the other embodiments,
[0121] [ka] It is.
[0122] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Het 1 teeth, each optionally substituted according to any one of the other embodiments,
[0123] [ka] It is.
[0124] In one embodiment, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Cy 1 teeth, Optionally, substituted according to any one of the other embodiments,
[0125] [ka] It is.
[0126] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Het 2 teeth, Optionally, substituted according to any one of the other embodiments,
[0127] [ka] It is.
[0128] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Het 2 teeth, each optionally substituted according to any one of the other embodiments,
[0129] [ka] It is.
[0130] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Het 3 teeth, Optionally, substituted according to any one of the other embodiments,
[0131] [ka] It is.
[0132] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Het 2 each independently represents a 5- to 6-membered monocyclic aromatic ring containing one or two heteroatoms selected from O, S, and N, and the aromatic ring is optionally, each independently, OR i , S.R. i , N.R. j R k , CN, Halo, CF3, and optionally, OR i , S.R. i C substituted with one substituent selected from the group consisting of , CN, and halo; 1~4 and substituted with 1 or 2 substituents selected from the group consisting of alkyl.
[0133] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R 1a and R 1b Together with the N atom to which it is bonded, each optionally substituted according to any one of the other embodiments,
[0134] [ka] together to form a
[0135] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R 1a and R 1b Together with the N atom to which it is bonded, each optionally substituted according to any one of the other embodiments,
[0136] [ka] together to form a
[0137] In certain embodiments, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein R d and R e together with the N atom to which it is attached to form 1-morpholinyl.
[0138] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Het 2 is attached to the remainder of the molecule of formula (I) by any available ring carbon atom.
[0139] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Het 2 is attached to the remainder of the molecule of formula (I) by any available ring nitrogen atom.
[0140] In one embodiment, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Cy 1 is attached to the remainder of the molecule of formula (I) by any available ring carbon atom.
[0141] In one embodiment, the present invention relates to compounds of formula (I), as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein Cy 1 is attached to the remainder of the molecule of formula (I) by any available ring nitrogen atom.
[0142] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein the compounds of formula (I) are limited to compounds of formula (I-1):
[0143] [ka]
[0144] It will be apparent that all variables in the structure of formula (I-1) are defined as defined for the compounds of formula (I) or any subgroup thereof, as set forth in any of the other embodiments.
[0145] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein the compounds of formula (I) are limited to compounds of formula (I-a'):
[0146] [ka]
[0147] It will be apparent that all variables in the structure of formula (I-a') are defined as defined for the compounds of formula (I) or any subgroup thereof, as set forth in any of the other embodiments.
[0148] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein the compounds of formula (I) are limited to compounds of formula (I-a1):
[0149] [ka]
[0150] It will be apparent that all variables in the structure of formula (I-a1) are defined as defined for the compounds of formula (I) or any subgroup thereof, as set forth in any of the other embodiments.
[0151] In one embodiment, the present invention relates to those compounds of formula (I) as described in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein the compounds of formula (I) are limited to compounds of formula (I-b'):
[0152] [ka]
[0153] It will be apparent that all variables in the structure of formula (I-b') are defined as defined for the compounds of formula (I) or any subgroup thereof, as set forth in any of the other embodiments.
[0154] In one embodiment, the present invention relates to the compounds of formula (I) as recited in any of the other embodiments, and pharma- ceutically acceptable salts and solvates thereof, or any subgroup thereof, wherein the compounds of formula (I) are limited to compounds of formula (I-b1):
[0155] [ka]
[0156] It will be apparent that all variables in the structure of formula (I-b1) are defined as defined for the compounds of formula (I) or any subgroup thereof, as set forth in any of the other embodiments.
[0157] In certain embodiments, the present invention relates to subgroups of Formula (I) defined in the general reaction scheme:
[0158] In certain embodiments, the compound of formula (I) is an exemplified compound, and any of their free bases, pharma- ceutically acceptable salts, and solvates.
[0159] All possible combinations of the above embodiments are considered to be within the scope of the present invention.
[0160] Methods for the preparation of compounds In this section, and in all other sections, unless the context indicates otherwise, references to formula (I) also include all other subgroups and embodiments thereof defined herein.
[0161] The general preparation of some representative examples of compounds of formula (I) is described below, and in certain examples they are usually prepared from starting materials that are either commercially available or can be prepared by commercially available or published methods. The following schemes are merely illustrative of examples of the present invention and are not intended to limit the present invention in any way.
[0162] Alternatively, the compounds of the present invention can also be prepared by similar reaction protocols as described in the following general schemes in combination with standard synthetic processes commonly used by those skilled in the art, such as similar reaction protocols such as those described in WO2016033486, WO2017147410, and WO2018183418.
[0163] Those skilled in the art will appreciate that in the reactions depicted in the schemes, although this is not always explicitly shown, it may be necessary to protect reactive functional groups (e.g., hydroxy, amino, or carboxy groups) if these are desired in the final product to avoid their undesired participation in the reaction. In general, conventional protecting groups can be used in accordance with standard practice. The protecting groups can be removed at a later convenient stage using methods well known in the art.
[0164] Those skilled in the art will appreciate that in the reactions depicted in the schemes it may be advisable or necessary to carry out the reactions under an inert atmosphere, such as, for example, under an N2-gas atmosphere.
[0165] It will be apparent to one skilled in the art that it may be necessary to cool the reaction mixture prior to working on the reaction (e.g., referring to a series of operations required to isolate and purify the products of a chemical reaction, such as quenching, column chromatography, extraction, etc.).
[0166] Those skilled in the art will appreciate that heating the reaction mixture under stirring may enhance the reaction outcome. In some reactions, microwave heating may be used instead of conventional heating to reduce the overall reaction time.
[0167] Those skilled in the art will appreciate that alternative sequences of chemical reactions as shown in the schemes below may also lead to desired compounds of formula (I).
[0168] Those skilled in the art will appreciate that the intermediates and final compounds shown in the following schemes can be further functionalized according to methods well known to those skilled in the art. The intermediates and compounds described herein can be isolated in free form or as a salt or solvate thereof. The intermediates and compounds described herein can be synthesized in the form of a mixture of tautomers and stereoisomers, which can be separated from one another according to resolution procedures known in the art.
[0169] The meanings of chemical abbreviations used in the following schemes are as defined in the schemes or as defined in Table 1.
[0170] The following general scheme focuses on compounds of formula (I-a1) and subgroups thereof, but one skilled in the art will appreciate that similar reaction procedures can be used to synthesize compounds of formula (I-b1):
[0171] [ka]
[0172] Compounds of formula (Ia), wherein the variables are defined as defined in formula (I), can be prepared according to Scheme 1:
[0173] [ka] The intermediate of formula (II) can be prepared by reacting, for example, in the presence of a suitable palladium catalyst, such as [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, in a suitable solvent, such as tetrahydrofuran, at a suitable temperature, such as, for example, 80 or 100°C, and a suitable CO pressure, such as 30 bar. The intermediate of formula (II) is P 1 is a suitable protecting group such as, for example, para-methoxybenzyl (PMB), with a suitable deprotecting agent such as, for example, trifluoroacetic acid, in a suitable solvent such as, for example, dichloromethane at a suitable temperature such as, for example, room temperature. The intermediate of formula (III) can be prepared by reacting the intermediate of formula (IV) with an amine in the presence of a suitable coupling agent, such as, for example, propanephosphonic anhydride, and a suitable base, such as, for example, triethylamine, in a suitable solvent, such as, for example, dichloromethane or ethyl acetate, at a suitable temperature, such as, for example, room temperature or 40° C. The intermediate of formula (IV) can be prepared by reacting the intermediate of formula (V) with an intermediate of formula (VI) ("Pin" means pinacol ester) and glyoxylic acid in a suitable solvent, such as, for example, methanol, at a suitable temperature, such as, for example, 40 or 60°C.
[0174] Or, R 4 Compounds of formula (Ia) where =H can also be prepared according to Scheme 2.
[0175] [ka] - the intermediate of formula (VII) can be prepared by reacting it with a carboxylic acid in the presence of a suitable amide forming reagent, such as, for example, HATU, HBTU, DCC or T3P, in the presence of a suitable base, such as, for example, triethylamine, in a suitable solvent, such as, for example, DMF, at a suitable temperature, such as, for example, room temperature. The intermediate of formula (VII) may be prepared by reacting the intermediate of formula (VIII) with a suitable amide forming reagent, such as, for example, diethyl cyanophosphonate, in a suitable solvent, such as, for example, DMF, at a suitable temperature, such as, for example, room temperature. The intermediate of formula (VIII) is P 3 is a suitable protecting group such as, for example, methyl, in the presence of a suitable base such as, for example, lithium hydride in a suitable solvent such as tetrahydrofuran or methanol or water, or a mixture thereof, at a suitable temperature such as, for example, room temperature or 50° C. The intermediate of formula (IX) can be prepared by reacting the intermediate of formula (X) with a suitable chlorinating agent, such as, for example, chlorodiphenylphosphine, followed by treatment with an amine source, such as, for example, ammonia gas, in a suitable solvent, such as, for example, THF, at a suitable temperature, such as, for example, 0° C. The intermediate of formula (X) can be prepared by protecting the intermediate of formula (XI) with TBSCl (where "TBS" means tert-butyldimethylsilyl), in the presence of a suitable base, such as, for example, triethylamine, in a suitable solvent, such as, for example, dichloromethane. The intermediate of formula (XI) is P 1 wherein is a suitable protecting group such as, for example, para-methoxybenzyl (PMB), with a suitable deprotecting agent such as, for example, trifluoroacetic acid, in a suitable solvent such as, for example, dichloromethane at a suitable temperature such as, for example, room temperature. The intermediate of formula (XII) can be prepared by reacting the intermediate of formula (XIII) with an amine using a suitable coupling agent, such as, for example, propanephosphonic anhydride, in the presence of a suitable base, such as, for example, triethylamine, in a suitable solvent, such as, for example, dichloromethane or ethyl acetate, at a suitable temperature, such as, for example, room temperature or 40° C. The intermediate of formula (XIII) can be prepared by reacting the intermediate of formula (XIV) with an intermediate of formula (VI) ("Pin" means pinacol ester) and glyoxylic acid in a suitable solvent, such as, for example, methanol, at a suitable temperature, such as, for example, 40 or 60°C. The intermediate of formula (XIV) is P 2 is a suitable protecting group, such as, for example, Boc, with a suitable deprotecting agent, such as, for example, trifluoroacetic acid, at a suitable temperature, such as, for example, room temperature.
[0176] Intermediates of formula (V) and (XV) 1 , X 2 , X 3 , Y, and n are as defined in formula (I); 2 is a suitable protecting group such as, for example, Boc, and P 3 is as defined in Scheme 2) can be prepared according to Scheme 3.
[0177] [ka] - reacting the intermediate of formula (XVI) with a suitable alcohol P, such as, for example, methanol 3 It can be prepared by reacting in a CO insertion reaction with OH in the presence of a suitable palladium catalyst, such as [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, in a suitable solvent, such as tetrahydrofuran, at a suitable temperature, such as 80 or 100°C, and at a suitable CO pressure, such as 30 bar. Alternatively, the intermediate of formula (XV) can be prepared by reacting an intermediate of formula (XIX) with an intermediate of formula (XVIII) in the presence of a suitable reducing agent, such as, for example, sodium cyanoborohydride or sodium triacetoxyborohydride, in a suitable solvent, such as, for example, dichloromethane or acetic acid or a mixture thereof, at a suitable temperature, such as, for example, 0° C. or room temperature. The intermediate of formula (XIX) can be prepared by reacting the intermediate of formula (XVII) with a suitable alcohol P, such as, for example, methanol 3 It can be prepared by reacting in a CO insertion reaction with OH in the presence of a suitable palladium catalyst, such as [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, in a suitable solvent, such as tetrahydrofuran, at a suitable temperature, such as 80 or 100°C, and at a suitable CO pressure, such as 30 bar. The intermediate of formula (V) is P 2 is a suitable protecting group such as, for example, Boc, with a suitable deprotecting agent, such as, for example, trifluoroacetic acid, at a suitable temperature, such as, for example, room temperature. The intermediate of formula (XVI) can be prepared by reacting an intermediate of formula (XVII) with an intermediate of formula (XVIII) in the presence of a suitable reducing agent, such as, for example, sodium cyanoborohydride or sodium triacetoxyborohydride, in a suitable solvent, such as, for example, dichloromethane or acetic acid or a mixture thereof, at a suitable temperature, such as, for example, 0° C. or room temperature.
[0178] P 2 The synthesis of XVIII where is Boc corresponds to the cases where n=1 (CAS[200184-45-8]) and n=2 (CAS[69610-41-9]).
[0179] The intermediate of formula (IX) 1 , X 2 , X 3 is CH and Y is as defined in formula (I)) can be prepared according to Scheme 4.
[0180] [ka] The enantiomers of formula (XXI) may be prepared by separation, for example using a suitable separation technique such as chiral SFC. The intermediate of formula (XXI) can be obtained by reacting the intermediate of formula (XXII) with a suitable reducing agent, such as, for example, iron dust, in a suitable solvent, such as, for example, acetic acid, at a suitable temperature, such as, for example, 70° C. It will be clear to the skilled person that the obtained aniline can be condensed intramolecularly with an aldehyde to an imine, which can be further reduced with a suitable reducing agent, such as, for example, sodium triacetoxyborohydride (NaBH(OAc)3), in a suitable solvent, such as, for example, dichloromethane (DCM), at a suitable temperature, such as, for example, room temperature. The intermediate of formula (XXII) can be prepared by reacting the intermediate of formula (XXIII) with a suitable oxidizing agent, such as, for example, dimethylsulfoxide (DMSO) and oxalyl chloride, in the presence of a suitable base, such as, for example, triethylamine, in a suitable solvent, such as, for example, DCM, at a suitable temperature, such as, for example, −78° C. or room temperature (rt). The intermediate of formula (XXIII) can be prepared by reacting the intermediate of formula (XXIV) with 1-fluoro-4-iodo-2-nitrobenzene (CAS[364-75-0]) in the presence of a suitable base, such as, for example, KCO, in a suitable solvent, such as, for example, acetonitrile, at a suitable temperature, such as, for example, 50° C.
[0181] Intermediates of formula (XV) may be prepared according to Scheme 5.
[0182] [ka] - an intermediate of formula (VI), 1is a suitable protecting group such as, for example, p-methoxybenzyl) with a suitable deprotecting agent such as, for example, trifluoroacetic acid, in a suitable solvent such as, for example, dichloromethane at a suitable temperature such as, for example, 0° C. or room temperature. The intermediate of formula (VI) can be prepared by reacting the intermediate of formula (XXVI) with bis(pinacolato)diboron in the presence of a suitable additive, such as, for example, triphenylphosphine, in the presence of a suitable base, such as, for example, dipotassium phosphate, in the presence of a suitable catalyst, such as, for example, copper(I) oxide, in a suitable solvent, such as, for example, methanol, at a suitable temperature, such as, for example, room temperature. The intermediate of formula (XXVI) can be prepared by reacting the intermediate of formula (XXVII) with dimethyl(1-diazo-2-oxopropyl)phosphonic acid in the presence of a suitable base, such as, for example, potassium carbonate, in a suitable solvent, such as, for example, methanol, at a suitable temperature, such as, for example, 0° C. The intermediate of formula (XXVII) can be prepared either by ozonolysis of the intermediate of formula (XXVIII) in a suitable solvent such as, for example, dichloromethane or methanol at a suitable temperature such as, for example, −78° C., or by oxidation of the intermediate of formula (XXVIII) with a suitable reagent such as, for example, a catalytic amount of osmium tetroxide, including, for example, sodium periodate, in a suitable solvent such as, for example, a mixture of tetrahydrofuran and water, at a suitable temperature such as, for example, room temperature.
[0183] P 1 p-Methoxybenzyl and R 4 (XXVIII) is the methyl corresponding to (CAS[1883727-77-2]). 1 p-Methoxybenzyl and R 4 (XXVIII) is the hydrogen corresponding to (CAS[1883727-89-6]).
[0184] It will be understood that, where appropriate functional groups are present, the compounds of the various formulae, or any intermediates used in their preparation, may be further derivatized by one or more standard synthetic methods employing condensation, substitution, oxidation, reduction, or cleavage reactions. Particular substitution techniques include conventional alkylation, arylation, heteroarylation, acylation, sulfonylation, halogenation, nitration, formylation, and coupling procedures.
[0185] The compounds of formula (I) may be synthesized in the form of racemic mixtures of enantiomers, which may be separated from each other according to resolution procedures known in the art. Racemic compounds of formula (I) containing a basic nitrogen atom may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. The diastereomeric salt forms are then separated, for example, by selective or fractional crystallization, and the enantiomers are liberated therefrom by alkali. An alternative method for separating the enantiomeric forms of the compounds of formula (I) includes liquid chromatography using a chiral stationary phase. The pure stereochemically isomers may also be derived from the corresponding pure stereochemically isomers of the appropriate starting materials, provided that the reaction occurs stereospecifically.
[0186] In the preparation of the compounds of the present invention, protection of remote functional groups (e.g., primary or secondary amines) of intermediates may be necessary. The need for such protection will vary with the nature of the remote functional group and the conditions of the preparation method. Suitable amino-protecting groups (NH-Pg) include acetyl, trifluoroacetyl, t-butoxycarbonyl (Boc), benzyloxycarbonyl (CBz), and 9-fluorenylmethyleneoxycarbonyl (Fmoc). The need for such protection is readily determined by one skilled in the art. For a general description of protecting groups and their use, see TW Greene and PG M Huts, Protective Groups in Organic Synthesis, 4th ed., Wiley, Hoboken, New Jersey, 2007.
[0187] Compound pharmacology The compounds of the present invention have been found to inhibit one of the higher MCL-1 activities, such as MCL-1 anti-apoptotic activity.
[0188] MCL-1 inhibitors are compounds that block one or more functions of MCL-1, such as its ability to bind to and inhibit the pro-apoptotic effectors Bak and Bax or BH3-only sensitizers, such as Bim, Noxa, or Puma.
[0189] The compounds of the invention are capable of inhibiting MCL-1 pro-survival functions and may therefore be useful in the treatment and / or prevention, particularly in the treatment, of diseases susceptible to the effects of the immune system, such as cancer.
[0190] In another embodiment of the invention, the compounds of the invention exhibit anti-tumor properties, for example, through immune modulation.
[0191] In one embodiment, the present invention is directed to a method for treating and / or preventing cancer, wherein the cancer is selected from those described herein, the method comprising administering to a subject (preferably a human) in need thereof a therapeutically effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof.
[0192] In one embodiment, the present invention is directed to a method for treating and / or preventing cancer, the method comprising administering to a subject, preferably a human, in need thereof a therapeutically effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein the cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), B-cell lymphoblastic leukemia, B-cell chronic lymphocytic leukemia (CLL), bladder cancer, breast cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon adenocarcinoma, diffuse large B-cell lymphoma, esophageal cancer, follicular lymphoma, gastric cancer, head and neck cancer (head and neck cancer). and / or pulmonary squamous cell carcinoma, hematopoietic cancer, hepatocellular carcinoma, Hodgkin's lymphoma, liver cancer, lung cancer (including but not limited to lung adenocarcinoma), lymphoma, medulloblastoma, melanoma, monoclonal gammopathy of undetermined significance, multiple myeloma, myelodysplastic syndrome, myelofibrosis, myeloproliferative neoplasms, ovarian cancer, ovarian clear cell carcinoma, ovarian serous cystadenoma, pancreatic cancer, polycythemia vera, prostate cancer, rectal adenocarcinoma, renal cell carcinoma, asymptomatic multiple myeloma, T-cell acute lymphoblastic leukemia, T-cell lymphoma, and Waldenstrom's macroglobulinemia.
[0193] In another embodiment, the present invention is directed to a method for treating and / or preventing cancer, the method comprising administering to a subject, preferably a human, in need thereof a therapeutically effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein the cancer is preferably acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), B-cell lymphoblastic leukemia, B-cell chronic lymphocytic leukemia (CLL), breast cancer, chronic lymphocytic leukemia (CLM), In one embodiment, the patient is selected from the group consisting of hematologic malignancies, chronic myeloid leukemia, diffuse large B-cell lymphoma, follicular lymphoma, hematopoietic cancer, Hodgkin's lymphoma, lung cancer (including but not limited to lung adenocarcinoma) lymphoma, monoclonal gammopathy of undetermined significance, multiple myeloma, myelodysplastic syndrome, myelofibrosis, myeloproliferative neoplasms, asymptomatic multiple myeloma, T-cell acute lymphoblastic leukemia, T-cell lymphoma, and Waldenstrom's macroglobulinemia.
[0194] In another embodiment, the present invention is directed to a method for treating and / or preventing cancer, the method comprising administering to a subject, preferably a human, in need thereof a therapeutically effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein the cancer is selected from the group consisting of adenocarcinoma, benign monoclonal gammopathy, biliary tract cancer (including but not limited to cholangiocarcinoma), bladder cancer, breast cancer (adenocarcinoma of the breast, papillary carcinoma of the breast, mammary carcinoma, bladder cancer, and ovarian cancer). cancer, including but not limited to medullary carcinoma of the breast), brain tumors (including but not limited to meningiomas), gliomas (including but not limited to astrocytoma, oligodendroglioma, medulloblastoma), bronchial carcinoma, cervical cancer (including but not limited to cervical adenocarcinoma), chordoma, choriocarcinoma, colorectal cancer (including but not limited to colon carcinoma, rectal carcinoma, colorectal adenocarcinoma), epithelial carcinoma, endothelial sarcoma (including but not limited to Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma), endometrial cancer (including but not limited to uterine carcinoma, uterine sarcoma), esophageal cancer (including but not limited to esophageal adenocarcinoma, Barrett's), Ewing's sarcoma, gastric cancer (including but not limited to gastric adenocarcinoma), gastrointestinal stromal tumors tumor, GIST), head and neck cancer (including but not limited to head and neck squamous cell carcinoma), hematopoietic cancer (leukemias such as acute lymphocytic leukemia (ALL) (including but not limited to B-cell ALL, T-cell ALL), acute myeloid leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL), as well as leukemias such as Hodgkin lymphoma (HL) (including but not limited to B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., diffuse large cell lymphoma, DLCL) (e.g., diffuse large B-celllymphomas such as B-cell NHL, such as chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (including but not limited to mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (including but not limited to Waldenstrom's macroglobulinemia), immunoblastic large cell lymphoma, hairy cell leukemia (HCL), precursor B-lymphoblastic lymphoma, and primary central nervous system (CNS) lymphoma. lymphomas of the central nervous system (CNS), T-cell NHL such as precursor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphomas (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (including but not limited to mycosis, Sézary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma, mixed leukemia / lymphomas of one or more of the above, multiple myeloma (MM), heavy chain disease (including but not limited to alpha chain disease, gamma chain disease, mu chain disease), immune cell amyloidosis, kidney cancer (including but not limited to nephroblastoma, also known as Wilms tumor, renal cell carcinoma), liver cancer (hepatocellular carcinoma, lung cancer (including but not limited to bronchogenic carcinoma, non-small cell lung cancer (NSCLC), squamous cell lung cancer (SLC), adenocarcinoma of the lung, Lewis lung carcinoma, pulmonary neuroendocrine tumor, typical carcinoid, atypical carcinoid, small cell lung cancer,Myelofibrosis (AMM), also known as myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES), ovarian cancer (including but not limited to cystadenocarcinoma, ovarian embryonal carcinoma, and ovarian adenocarcinoma), pancreatic cancer (including but not limited to pancreatic adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic adenocarcinoma), pancreatic adenocarcinoma (including but not limited to pancreatic adenocarcinoma, pancreatic adenocarcinoma, and pancreatic intraductal papillary mucinous neoplasm), pancreatic fibrosis (including but not limited to pancreatic adenocarcinoma, pancreatic fibrosis, and pancreatic fibrosis), pancreatic fibrosis (including but not limited to pancreatic fibrosis ... neoplasm, IPMN), pancreatic islet cell tumors), prostate cancer (including but not limited to prostate adenocarcinoma), skin cancer (including but not limited to squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)), and soft tissue sarcomas (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma).
[0195] In another embodiment, the present invention is directed to a method for treating and / or preventing cancer, the method comprising administering to a subject, preferably a human, in need thereof a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein the cancer is selected from the group consisting of benign monoclonal gammopathy, breast cancer (adenocarcinoma of the breast, papillary carcinoma of the breast, mammary carcinoma, and the like). cancer, including but not limited to medullary carcinoma of the breast), hematopoietic cancers (acute lymphocytic leukemia (ALL) (including but not limited to B-cell ALL, T-cell ALL), acute myeloid leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myeloid leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL), as well as Hodgkin's lymphoma (HL) (including but not limited to B-cell HL, T-cell HL) and non-Hodgkin's lymphoma (NHL) (e.g., diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma lymphomas such as B-cell NHL, follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (including but not limited to mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (including but not limited to Waldenstrom's macroglobulinemia),T-cell NHL such as immunoblastic large cell lymphoma, hairy cell leukemia (HCL), precursor B-lymphoblastic lymphoma, and primary central nervous system (CNS) lymphoma, precursor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphomas (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (including but not limited to mycoses, Sézary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma, mixed leukemia / lymphoma of one or more of the above, multiple myeloma (MM), heavy chain disease (including but not limited to alpha chain disease, gamma chain disease, mu chain disease), immune cell amyloidosis, liver cancer (including but not limited to hepatocellular carcinoma (HCC), malignant hepatocellular carcinoma), lung cancer (including but not limited to bronchogenic carcinoma, non-small cell lung cancer (NSCLC), squamous cell lung carcinoma (SLC), adenocarcinoma of the lung, Lewis lung carcinoma, pulmonary neuroendocrine tumor, typical carcinoid, atypical carcinoid, small cell lung carcinoma (SCLC), and large cell neuroendocrine carcinoma), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), prostate cancer (including but not limited to prostate adenocarcinoma).
[0196] In another embodiment, the present invention is directed to a method for treating and / or preventing cancer, the method comprising administering to a subject, preferably a human, in need thereof a therapeutically effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein the cancer is selected from the group consisting of prostate cancer, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, B-cell chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
[0197] In another embodiment, the present invention is directed to a method for treating and / or preventing cancer, the method comprising administering to a subject, preferably a human, in need thereof a therapeutically effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein the cancer is multiple myeloma.
[0198] The compounds according to the invention, or pharmaceutical compositions comprising said compounds, may also have therapeutic use in combination with immunomodulatory agents such as inhibitors of the PD1 / PDL1 immune checkpoint axis, e.g. antibodies (or peptides) which bind to and / or inhibit the activity of PD-1 or the activity of PD-L1, and / or CTLA-4, or engineered chimeric antigen receptor T cells (CART) which target tumor-associated antigens.
[0199] The compounds according to the invention, or pharmaceutical compositions comprising the compounds, may also be combined with radiotherapy or chemotherapeutic agents (including but not limited to anti-cancer agents), or any other pharmaceutical agent administered to a subject with cancer for the treatment of the cancer in the subject, or for the treatment or prevention of side effects associated with the treatment of the cancer in the subject.
[0200] The compounds according to the invention, or pharmaceutical compositions containing said compounds, may also be combined with other agents that stimulate or enhance the immune response, such as a vaccine.
[0201] In one embodiment, the present invention relates to a method for treating and / or preventing cancer (wherein the cancer is selected from those described herein), the method comprising administering to a subject (preferably a human) in need thereof a therapeutically effective amount of a co-therapy or combination therapy comprising a compound of formula (I) of the present invention and one or more anti-cancer agents selected from the group consisting of: (a) an immunomodulatory agent (such as an inhibitor of the PD1 / PDL1 immune checkpoint axis, such as an antibody (or peptide) that binds to and / or inhibits the activity of PD-1, or that binds to and / or inhibits the activity of PD-L1 and / or CTLA-4), (b) engineered chimeric antigen receptor T cells (CART) targeting a tumor-associated antigen, (c) radiation therapy, (d) chemotherapy, and (e) an agent that stimulates or enhances an immune response, such as a vaccine.
[0202] The present invention is directed to the compounds of formula (I) and their pharma- ceutically acceptable salts and solvates, for use as pharmaceuticals.
[0203] The present invention is directed to compounds of formula (I), and pharma- ceutically acceptable salts and solvates thereof, for use in inhibiting MCL-1 activity.
[0204] As used herein, unless otherwise specified, the term "anti-cancer agent" is intended to encompass "anti-tumor cell growth agents" and "anti-neoplastic agents."
[0205] The present invention is directed to compounds of formula (I) and their pharma- ceutically acceptable salts and solvates for use in the treatment and / or prophylaxis of the above mentioned diseases, preferably cancer.
[0206] The present invention is directed to compounds of formula (I) and their pharma- ceutically acceptable salts and solvates for the treatment and / or prevention of the above mentioned diseases, preferably cancer.
[0207] The present invention is directed to compounds of formula (I) as described herein, and their pharma- ceutically acceptable salts and solvates, for the treatment and / or prevention, in particular for the treatment, of diseases, preferably cancer.
[0208] The present invention is directed to compounds of formula (I) and their pharma- ceutically acceptable salts and solvates, as described herein, for use in the treatment and / or prophylaxis, in particular the treatment, of diseases, preferably cancer (e.g. multiple myeloma).
[0209] The present invention is directed to compounds of formula (I) and pharma- ceutically acceptable salts and solvates thereof for the treatment and / or prevention, in particular for the treatment, of an MCL-1 mediated disease or condition, preferably cancer, more preferably a cancer as described herein (e.g., multiple myeloma).
[0210] The present invention is directed to compounds of formula (I) and pharma- ceutically acceptable salts and solvates thereof for use in the treatment and / or prophylaxis of an MCL-1 mediated disease or condition, preferably cancer, more preferably a cancer as described herein (e.g. multiple myeloma), in particular for use in the treatment.
[0211] The present invention is directed to compounds of formula (I) and their pharma- ceutically acceptable salts and solvates for the manufacture of a medicament.
[0212] The present invention is directed to compounds of formula (I) and pharma- ceutically acceptable salts and solvates thereof for the manufacture of a medicament for the inhibition of MCL-1.
[0213] The present invention is directed to compounds of formula (I) and their pharma- ceutically acceptable salts and solvates for the manufacture of a medicament for the treatment and / or prevention, in particular for the treatment, of cancer, preferably the cancers described herein. More particularly, the cancer is a cancer that responds to the inhibition of MCL-1 (e.g. multiple myeloma).
[0214] The present invention is directed to compounds of formula (I) and their pharma- ceutically acceptable salts and solvates for the manufacture of medicaments for the treatment and / or prevention, in particular for the treatment, of any one of the above mentioned disease conditions.
[0215] The present invention is directed to compounds of formula (I) and their pharma- ceutically acceptable salts and solvates for the manufacture of a medicament for the treatment and / or prevention of any one of the above mentioned disease conditions.
[0216] The compounds of formula (I) and their pharma- ceutically acceptable salts and solvates may be administered to a subject, preferably a human, for the treatment and / or prevention of any one of the above-mentioned diseases.
[0217] In view of the availability of the compounds of formula (I), and their pharma- ceutically acceptable salts and solvates, there is provided a method of treating a subject, preferably a mammal such as a human, suffering from any of the above-mentioned diseases, or slowing the progression of any of the above-mentioned diseases in a subject, a human, or preventing a subject, preferably a mammal such as a human, from suffering from any one of the above-mentioned diseases.
[0218] The method includes administration, i.e., systemic or local, preferably oral or intravenous, more preferably oral, of an effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof to a subject, such as a human.
[0219] Those skilled in the art will recognize that a therapeutically effective amount of a compound of the present invention is an amount sufficient to have therapeutic activity, which amount will vary depending on, among other things, the type of disease, the concentration of the compound in the therapeutic formulation, and the condition of the patient. In one embodiment, the daily therapeutically effective amount may be about 0.005 mg / kg to 100 mg / kg.
[0220] The amount of the compound according to the present invention, also referred to herein as active ingredient, required to achieve a therapeutic effect may vary on an individual basis, for example, depending on the specific compound, the route of administration, the age and condition of the recipient, and the specific disorder or disease being treated. The method of the present invention may also include administering the active ingredient in a regimen of 1 to 4 intakes per day. In these methods of the present invention, the compound according to the present invention is preferably formulated prior to administration.
[0221] The present invention also provides a composition for treating and / or preventing a disorder referred to herein, preferably a cancer as described herein, comprising a therapeutically effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable carrier or diluent.
[0222] While it is possible for the active ingredient (e.g., the compound of the present invention) to be administered alone, it is preferable to administer it as a pharmaceutical composition.Thus, the present invention further provides a pharmaceutical composition comprising a compound according to the present invention together with a pharma-ceutically acceptable carrier or diluent.The carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
[0223] The pharmaceutical composition of the present invention can be prepared, for example, by the method described in Gennaro et al., Remington's Pharmaceutical Sciences (18 th They may be prepared by any method well known in the art of pharmacy, such as those described in "Pharmaceutical preparations and their Manufacture," ed., Mack Publishing Company, 1990, especially Part 8: Pharmaceutical preparations and their Manufacture.
[0224] The compounds of the invention can be used alone or in combination with one or more additional therapeutic agents. Combination therapy includes administering a single pharmaceutical dosage formulation containing a compound according to the invention and one or more additional therapeutic agents, as well as administering a compound according to the invention and each additional therapeutic agent in its own separate pharmaceutical dosage formulation.
[0225] Thus, in one embodiment, the present invention is directed to a product comprising a compound according to the invention as a first active ingredient and further one or more anti-cancer agents as additional active ingredients as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from cancer.
[0226] One or more other anti-cancer agents and the compounds according to the present invention may be administered simultaneously (e.g., in separate or single compositions) or sequentially in any order. In one embodiment, two or more compounds are administered within a period and / or in an amount and / or manner sufficient to ensure that an advantageous or synergistic effect is achieved. It will be understood that the preferred method and order of administration for each component of the combination, as well as the respective dosages and regimes, will depend on the particular other anti-cancer agents and compounds according to the present invention administered, their routes of administration, the particular condition, particularly the tumor, being treated, and the particular host being treated.
[0227] The following examples further illustrate the invention. EXAMPLES
[0228] Several methods for preparing the compounds of the invention are illustrated in the following examples. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification or could be synthesized by one of ordinary skill in the art using published methods.
[0229] [Table 1]
[0230] As will be appreciated by one of skill in the art, compounds synthesized using the protocols provided may contain residual solvents or small amounts of impurities.
[0231] Those skilled in the art will understand that, even if not explicitly mentioned in the experimental protocols below, typically after column chromatography purification, the desired fractions were collected and the solvent was evaporated.
[0232] When stereochemistry is not indicated, this is meant to be a mixture of stereoisomers unless otherwise indicated or clear from the context.
[0233] Where stereobonds are shown in the structures of intermediates and compounds of the present invention, the stereochemistry is meant to be absolute and determined, regardless of whether a stereodescriptor is also attached.
[0234] Preparation of intermediates For intermediates that were used in the next reaction step either as crude intermediates or as partially purified intermediates, in some cases no molar amount is mentioned for such intermediate in the next reaction step or an estimated or theoretical molar amount is indicated for such intermediate in the next reaction step in the reaction protocols described below.
[0235] tert-Butyl (S)-2-formylazetidine-1-carboxylate (I-1)
[0236] [ka]
[0237] Dess-Martin periodinane [87413-09-0] (30 g, 1.3 equiv.) was added to a stirred solution of (S)-1-Boc-2-azetidinemethanol [161511-85-9] (10 g, 53.4 mmol) in DCM (250 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was quenched by the addition of a solution of sodium thiosulfate in saturated NaHCO3 solution. The resulting mixture was vigorously stirred for 15 min. The resulting suspension was filtered through a pad of Celite®. The filter pad was washed with dichloromethane. The combined filtrate was separated and the aqueous layer was extracted with DCM (2×). The combined organic layers were washed twice with saturated aqueous NaHCO3, dried over MgSO4, and filtered. The filtrate's solvent was evaporated to give 10.17 g of intermediate 1 (estimated quantitative yield) as an oil, which was used without further purification.
[0238] tert-Butyl (S)-2-((1H-benzo[d][1,2,3]triazol-1-yl)(hydroxy)methyl)azetidine-1-carboxylate (I-2)
[0239] [ka]
[0240] tert-Butyl methyl ether (40 mL) was added to I-1 (9 g, 48.59 mmol). The resulting suspension was stirred at room temperature for 10 min and then filtered. The solid was rinsed with tert-butyl methyl ether. The filtrate was transferred to a round-bottom flask and then cooled to 0° C. 1H-benzotriazole (5.79 g, 1 equiv.) was added to the solution and the reaction mixture was stirred at room temperature for 18 h. The solvent was evaporated to give intermediate 2 (14.79 g, estimated quantitative yield), which was used without further purification.
[0241] 2-(((2R,3S)-3-Methylhex-5-en-2-yl)thio)pyrimidine (I-3)
[0242] [ka]
[0243] A solution of DEAD (25.79 mL, 1.7 equiv.) in THF (100 mL) was added dropwise to PBu3 (36.09 mL, 1.5 equiv.) in degassed THF (300 mL) at 0° C. under nitrogen atmosphere. A solution of (2S,3S)-3-methylhex-5-en-2-ol [125225-80-1] (11 g, 1 equiv.) in THF (200 mL) was added dropwise to the mixture at 0° C. The mixture was stirred at 0° C. for 30 min (the solution turned pale orange). Pyrimidine-2-thiol [131242-36-9] (30.79 g, 2.85 equiv.) was added slowly to the mixture. The reaction mixture was stirred at 0° C. for 1 h and then at room temperature overnight. The reaction mixture was filtered. 500 mL of EtOAc was added to the filtrate. The solution was washed twice with 1 N K2CO3 (300 mL) and then twice with brine (300 mL). The aqueous layer was back-extracted with 400 mL of EtOAc. The combined organic layers were then dried over Na2SO4 and concentrated under vacuum. The residue was purified by flash column chromatography on silica gel (eluent: petroleum ether / EtOAc 100 / 0→0 / 100). The desired fractions were collected and the solvent was concentrated to dryness under vacuum to give intermediate 3 (35.4 g, 68% yield).
[0244] 2-(((2R,3S)-3-Methylhex-5-en-2-yl)sulfonyl)pyrimidine (I-4)
[0245] [ka]
[0246] To a mixture of Na2WO4 [10213-10-2] (1.075 g, 0.1 equiv.), phenylphosphonic acid [157171-33-1] (0.515 g, 0.1 equiv.), and tetrabutylammonium sulfate (3.75 mL, 0.1 equiv.) was added H2O2 (9.24 g, 2.5 equiv.) in one portion at room temperature. The mixture was aged at room temperature for 5 min, and then a solution of I-3 (10 g, 1 equiv.) in toluene (150 mL) was added in one portion. The resulting reaction mixture was heated to 50° C. and stirred vigorously. After 60 h, the reaction was cooled to room temperature. The reaction mixture was poured into water (150 mL). The layers were separated and the aqueous layer was extracted with EtOAc (300 mL×3). The filtrate was washed with saturated aqueous Na2S2O5 (200 mL×2), dried over MgSO4, filtered, and evaporated. The residue was purified by flash column chromatography on silica gel (eluent: petroleum ether / EtOAc 100 / 0→0 / 100). The desired fractions were collected and the solvent was concentrated under reduced pressure to give intermediate 4 (5.6 g, 68%) as a yellow oil.
[0247] Sodium (2R,3S)-3-methylhex-5-ene-2-sulfonate (I-5)
[0248] [ka]
[0249] A solution of I-4 (5.6 g, 1 equiv.) in MeOH (30 mL) was cooled to 0° C. and treated with NaOMe (4.794 g, 1 equiv.). The mixture was allowed to warm to room temperature for 20 min. The solvent was removed in vacuo. Water (10 mL) was added and the mixture was extracted with EtOAc (10 mL×3). The combined organic layers were concentrated in vacuo to give intermediate 5 (6.3 g, estimated quantitative yield) as a yellow solid. The product was used in the next step without further purification.
[0250] (2R,3S)-3-Methylhex-5-ene-2-sulfonamide (I-6)
[0251] [ka]
[0252] I-5 (33.2 g, 1 equiv.) was dissolved in MeOH (200 mL) and treated with NaOAc (18.48 g, 1.25 equiv.) followed by a solution of hydroxylamine O-sulfonic acid (25.48 g, 1.25 equiv.) in water (15 mL). The reaction was stirred overnight at room temperature. The mixture was neutralized with solid NaHCO3 and extracted with EtOAc (400 mL x 3). The combined organic layers were dried over MgSO4, filtered and concentrated. The residue was purified by flash column chromatography on silica gel (eluent: petroleum ether / EtOAc 100 / 0 -> 0 / 100). The desired fractions were collected and the solvent was concentrated under vacuum to give intermediate 6 (18.1 g, 56%) as a clear oil.
[0253] (2R,3S)-3-Methylhex-5-ene-2-sulfonamide (I-7)
[0254] [ka]
[0255] To a solution of I-6 (5 g, 28.2 mmol) in DMF (50 mL) was slowly added K2CO3 (15.593 g, 4 equiv.) followed by 4-methoxybenzyl chloride (11.474 mL, 3 equiv.). Upon completion of the addition, the reaction was heated to 70 °C and stirred at room temperature overnight. The reaction was filtered through a pad of dicalite® and the filtrate was concentrated under reduced pressure to give a pale yellow oil. The oil was dissolved in EtOAc (150 mL) and washed with brine (2 x 100 mL). The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure to give a pale orange oil. The crude product was purified by flash column chromatography on silica gel (heptane: EtOAc - 1:0 to 8:2). After evaporation of the product-containing fractions, the residue was purified by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-10 μm, 50 × 150 mm, mobile phase: 0.25% NH4HCO3 in water, CH3CN) to give intermediate 7 (5.98 g, yield: 48%) as a white solid.
[0256] (2R,3S)-N,N-bis(4-methoxybenzyl)-3-methyl-5-oxopentane-2-sulfonamide (I-8)
[0257] [ka]
[0258] I-7 (1 g, 2.275 mmol) was dissolved in a mixture of DCM (12.5 mL) and MeOH (12.5 mL) and the resulting mixture was cooled to -78 °C. Ozone (109.199 mg, 1 equiv) was then bubbled through the reaction mixture until a persistent blue color was observed (5 min). Nitrogen was then bubbled through the solution (static at -78 °C) to remove the blue color, followed by the addition of PPh3 (2.984 g, 5 equiv). Once the addition was complete, the reaction was left stirring at -78 °C for 1 h. The reaction mixture was then slowly warmed to room temperature and stirred for 1 h. The heterogeneous mixture was filtered through a pad of dicalite®. The pad was washed thoroughly with DCM. The filtrate was concentrated under reduced pressure to give a green oil, which was purified by flash column chromatography on silica gel (heptane:EtOAc 1:0 to 3:1) to give intermediate 8 (920 mg, 87% yield) as a colorless solid.
[0259] (2R,3S)-N,N-bis[(4-methoxyphenyl)methyl]-3-methyl-hex-5-yne-2-sulfonamide (I-37)
[0260] [ka]
[0261] Dimethyl(1-diazo-2-oxopropyl)phosphonate (0.3 mL, 1 equiv.) was added to a suspension of I-8 (800 mg, 1.9 mmol) and K2CO3 (527 mg, 2 equiv.) in MeOH (5 mL) at 0 °C. After 30 min at 0 °C, the reaction mixture was allowed to reach room temperature and stirring was continued for 4 h. The reaction mixture was diluted with 10 mL of DCM, filtered and the filtrate was evaporated. The residue was purified by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-10 μm, 50 × 150 mm, mobile phase: 0.25% NH4HCO3 in water, CH3CN) to give intermediate 37 (500 mg, yield: 63%).
[0262] (2R,3S,E)-N,N-bis(4-methoxybenzyl)-3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-5-ene-2-sulfonamide (I-38)
[0263] [ka]
[0264] A mixture of bis(pinacolato)diboron (187 mg, 1.5 equiv), copper(I) oxide (19.4 mg, 0.27 equiv), PPh3 (49 mg, 0.38 equiv), potassium phosphate dibasic (171 mg, 2 equiv) and MeOH (1.6 mL) was stirred in a tube. The tube was closed and purged with nitrogen for 10 min. I-37 (200 mg, 0.48 mmol) dissolved in MeOH (1.6 mL) was added. The reaction mixture was stirred at room temperature for 3 h. EtOAc (6 mL) was added. The reaction mixture was stirred for 5 min and filtered. The filtrate was evaporated, the residue was stirred in DIPE, the solid was filtered off and the filtrate was evaporated to give intermediate 38 (243 mg, yield: 93%) which was used without further purification.
[0265] (6-chloro-1-((4-iodo-2-nitrophenoxy)methyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methanol (I-18)
[0266] [ka]
[0267] The reaction was carried out in two batches. For each batch, 6-chloro-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol (CAS [1883726-74-6], 300 g, 1.32 mol) and 1-fluoro-4-iodo-2-nitrobenzene (353 g, 1.32 mol) were dissolved in acetonitrile (1.4 L). K2CO3 (549 g, 3.97 mol) was added to the reaction mixture, which was stirred at 50 °C for 16 h. The reaction mixture was filtered and the filtrate was evaporated. Then the two batches were combined and the residue was purified by column chromatography (SiO2, petroleum ether:dichloromethane = 3 / 1 to petroleum ether / EtOAc = 1:1). Intermediate 18 was obtained as a yellow oil (600 g, 48% yield).
[0268] 6-Chloro-1-((4-iodo-2-nitrophenoxy)methyl)-1,2,3,4-tetrahydronaphthalene-1-carbaldehyde (I-19)
[0269] [ka]
[0270] The reaction was carried out in three batches. For each batch, DMSO (99.0 g, 1.27 mol) was added to a solution of (COCl)2 (161 g, 1.27 mol) in DCM (2.4 L) at -78 °C. The reaction mixture was stirred at -78 °C for 15 min. Then, I-18 (200 g, 422 mmol) in DCM (0.90 L) was added at -78 °C and stirring was continued at -78 °C for 30 min. Et3N (214 g, 2.11 mol) was added at -78 °C and the reaction mixture was allowed to warm to room temperature. Stirring was continued at room temperature for 1.5 h. Saturated aqueous NaHCO3 (1 L) was added and the mixture was extracted with DCM (0.5 L x 2). The three batches were then combined and evaporated to give intermediate 19 (560 g) as a yellow solid, which was used without further purification.
[0271] (S)-6'-Chloro-7-iodo-3',4,4',5-tetrahydro-2H,2'H-spiro[benzo[b][1,4]oxazepine-3,1'-naphthalene] (I-20) (and its enantiomers)
[0272] [ka]
[0273] The reaction was carried out in three batches. Iron (153 g, 2.75 mol) was added to a solution of I-19 (185 g, 392 mmol) in AcOH (2.5 L) at 70° C., and the reaction mixture was stirred at 70° C. for 3 h. The solvent was evaporated and DCE (1.9 L) was added to the residue. NaBH(OAc)3 (333 g, 1.57 mol) was then added in small portions at 0° C. Stirring was continued at room temperature for 1 h. The three batches were combined. Citric acid (10%, in water, 5 L) was added, and the mixture was extracted with DCM (2 L×2). The combined organic layers were evaporated. The residue was purified by SFC (column: DAICEL CHIRALPAK AD (250×50 mm, 10 um); mobile phase: [0.1% NH3H2O in EtOH]; B%: 50%-50%, 8.5 min) to give intermediate 20 (95.2 g, yield: 40%) and its enantiomer (105.1 g, yield: 44%), both as yellow solids.
[0274] Tert-Butyl (S)-2-(((S)-6'-chloro-7-iodo-3',4'-dihydro-2H,2'H-spiro[benzo[b][1,4]oxazepine-3,1'-naphthalene]-5(4H)-yl)methyl)azetidine-1-carboxylate (I-21)
[0275] [ka]
[0276] A mixture of I-20 (7.58 g, 17.8 mmol) and I-2 (16.25 g, 53.4 mmol) was dissolved in DCM (75 mL) and AcOH (25 mL) was added. The mixture was stirred at room temperature for 30 min and then cooled to 0° C. Sodium triacetoxyborohydride (11.3 g, 53.4 mmol) was added in portions. After the addition, the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was poured in portions into a cooled (0° C.) solution of NaOH (21.3 g, 53.4 mmol) in 300 mL of water. After the addition, the mixture was diluted with DCM and water. The organic layer was separated, washed with water, dried over MgSO4, filtered and the filtrate's solvent was evaporated under reduced pressure. The residue was dissolved in DCM and purified by flash chromatography on silica (eluent: dichloromethane). The fractions containing the product were combined and the solvent was evaporated to give intermediate 21 (9.8 g, 92% yield).
[0277] (S)-5-(((S)-Azetidin-2-yl)methyl)-6'-chloro-7-iodo-3',4,4',5-tetrahydro-2H,2'H-spiro[benzo[b][1,4]oxazepine-3,1'-naphthalene] (I-22)
[0278] [ka]
[0279] A mixture of I-21 (9.8 g, 16.5 mmol) and DCM (125 mL) was stirred at room temperature. TFA (125 mL) was added dropwise. The reaction mixture was stirred at room temperature for 3 h and then evaporated to dryness while maintaining the temperature below 30 °C. The residue was dissolved in DCM and poured into aqueous NaHCO3. The layers were separated and the organic layer was extracted with DCM. The combined organic fractions were washed with water, dried over MgSO4 and evaporated. The residue was purified by flash chromatography on silica (eluent: DCM-MeOH / NH3 gradient 100% / 0% to 95% / 5%). Pure fractions were collected and evaporated. The residual oil was stirred in CH3CN until precipitation occurred. The precipitate was filtered off and dried to give intermediate 22 (5.1 g, 63% yield).
[0280] tert-Butyl (2S)-2-[[(3S)-6'-chloro-7-iodo-spiro[2,4-dihydro-1,5-benzoxazepine-3,1'-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (I-39)
[0281] [ka]
[0282] I-20 (13.197 g, 31 mmol) and N-Boc-L-prolinal (18.53 g, 3 equiv.) were dissolved in CHCl (150 mL) and then AcOH (35.5 mL, 20 equiv.) was added. The mixture was stirred at room temperature for 30 min and then cooled to 0° C. Sodium triacetoxyborohydride (19.711 g, 3 equiv.) was then added in portions. After the addition, the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was poured in portions into a cooled (0° C.) solution of NaOH (31 g) in 620 mL of water. After the addition, the mixture was diluted with CHCl and water. The organic layer was separated, washed with water, dried over MgSO, filtered and the filtrate's solvent was evaporated. The residue was purified by flash chromatography over silica gel (eluent: CHCl). The fractions containing the product were combined and the solvent was evaporated. The residue was purified again by HPLC (gradient ethyl acetate / hexanes) to give intermediate 39 (12.2 g, 64%).
[0283] (S)-6'-Chloro-7-iodo-5-(((S)-pyrrolidin-2-yl)methyl)-3',4,4',5-tetrahydro-2H,2'H-spiro[benzo[b][1,4]oxazepine-3,1'-naphthalene] (I-40)
[0284] [ka]
[0285] To a stirred solution of I-39 (14 g, 22.991 mmol) in anhydrous DCM (230 mL) was added TFA (23 mL, 1.49 g / mL, 300.551 mmol). The resulting mixture was stirred at room temperature for 20 h. The mixture was carefully quenched with saturated aqueous NaHCO3 and DCM. The organic layer was extracted, washed with brine (100 mL), dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure. The crude was used in the next step without further purification.
[0286] (I-41)
[0287] [ka]
[0288] A solution of I-38 (684 mg, 1.26 mmol), I-40 (640.33 mg, 1.26 mmol) and glyoxylic acid monohydrate (231.68 mg, 2.52 mmol) in MeOH (40.27 mL) was stirred at 65° C. for 16 h. The reaction mixture was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel using a gradient DCM / MeOH 95 / 5 as eluent to give intermediate 41 (1025 mg, 83% yield).
[0289] (I-42)
[0290] [ka]
[0291] 1-Propanephosphonic anhydride (454 μL, 0.38 mmol) was added dropwise to a stirred solution of I-41 (125 mg, 0.127 mmol), bis(2-methoxyethyl)amine (50.84 mg, 0.382 mmol) and TEA (125.5 μL, 0.905 mmol) in DCM (3.75 mL) at 0° C. The reaction mixture was stirred for 2 h. The reaction mixture was diluted with dichloromethane (10 mL) and poured into water. The aqueous layer was extracted with DCM. The organic layer was dried over MgSO4 and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel using a gradient DCM / MeOH 96 / 4 as eluent to give intermediate 42 (110 mg, 78% yield) as an oil.
[0292] (I-43)
[0293] [ka]
[0294] To a solution of I-42 (110 mg, 0.1 mmol) in DCM (3 mL) was added TFA (0.77 mL, 10 mmol) dropwise at 0° C. After the addition, the reaction mixture was warmed to 25° C. and stirred at this temperature for 16 h. The reaction mixture was diluted with DCM (30 mL) and added dropwise to a cold mixture of NaHCO3 (1.68 g, 20 mmol) and water (100 mL). The layers were separated and the aqueous layer was extracted with DCM (30 mL, ×1). The combined organic layers were dried over MgSO4, filtered and the solvent was removed under reduced pressure. The residue was purified by flash column chromatography on silica gel using a gradient DCM / MeOH 95 / 5 as eluent. Pure fractions were collected and the solvent was evaporated under reduced pressure. The residue was co-evaporated with toluene (×2) to give intermediate 43 (90 mg, estimated quantitative yield) as an oil.
[0295] (I-44)
[0296] [ka]
[0297] 1-Propanephosphonic anhydride (757.36 μL, 0.64 mmol) was added dropwise to a stirred solution of I-41 (250 mg, 0.25 mmol), methyl[2-(oxan-4-yl)ethyl]amine (CAS[1083216-46-9]) (91.12 mg, 0.64 mmol) and TEA (251.01 μL, 1.81 mmol) in DCM (7.53 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with dichloromethane and poured into water. The aqueous layer was extracted with DCM. The organic layer was dried over MgSO4 and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel using a gradient DCM / MeOH 96 / 4 as eluent to give intermediate 44 (230 mg, 82% yield).
[0298] (I-45)
[0299] [ka]
[0300] To a solution of I-44 (230 mg, 0.21 mmol) in DCM (3.25 mL) was added TFA (2.92 mL, 38.1 mmol) dropwise at 0° C. After the addition, the reaction mixture was warmed to 25° C. and stirred at this temperature for 16 h. The reaction mixture was diluted with DCM (30 mL) and added dropwise to a cold mixture of NaHCO3 (4268 mg, 50.8 mmol) and water (100 mL). The layers were separated and the aqueous layer was extracted with DCM (30 mL, ×1). The combined organic layers were dried over MgSO4, filtered and the solvent was removed under reduced pressure. The residue was purified by flash column chromatography on silica gel using a gradient DCM / MeOH 95 / 5 as eluent. Pure fractions were collected and the solvent was evaporated under reduced pressure. The residue was co-evaporated with toluene (×2) to give intermediate 45 (195 mg, estimated quantitative yield).
[0301] (I-46)
[0302] [ka]
[0303] 1-Propanephosphonic anhydride (454.4 μL, 0.382 mmol) was added dropwise to a stirred solution of I-41 (125 mg, 0.127 mmol), TEA (125 μL, 0.91 mmol) and N-methyl(tetrahydro-2H-pyran-4-yl)methanamine (49 mg, 0.38 mmol) in DCM (3.75 mL) at 0° C. After addition, the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with dichloromethane and poured into water. The aqueous layer was extracted with DCM. The organic layer was dried over MgSO4 and the solvent was evaporated. The residue was purified by flash column chromatography on silica gel using DCM / MeOH 96 / 4 as eluent to give intermediate 46 (140 mg, estimated quantitative yield).
[0304] (I-47)
[0305] [ka]
[0306] To a solution of I-46 (140 mg, 0.128 mmol) in DCM (3 mL) was added TFA (0.98 mL, 12.8 mmol) dropwise at 0° C. After the addition, the reaction mixture was stirred at 25° C. for 16 h. The reaction mixture was diluted with DCM (30 mL) and added dropwise to a cold mixture of NaHCO3 (2.15 g, 25.6 mmol) and water (100 mL). The organic layer was separated and the aqueous layer was extracted with DCM (×1, 30 mL). The combined organic layers were dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel using a gradient DCM / MeOH 95 / 5 as eluent. Pure fractions were collected and evaporated. The residue was co-evaporated with toluene (×2) to give intermediate 47 (90 mg, 82% yield) as an oil.
[0307] (I-48)
[0308] [ka]
[0309] 1-Propanephosphonic anhydride (757.36 μL, 0.64 mmol) was added dropwise to a stirred solution of I-41 (250 mg, 0.25 mmol), TEA (251.01 μL, 1.81 mmol) and dimethylamine (0.58 mL, 1.15 mmol) in DCM (7.53 mL) at 0° C. After addition, the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with dichloromethane and poured into water. The aqueous layer was extracted with DCM. The organic layer was dried over MgSO4 and the solvent was evaporated. The residue was purified by flash column chromatography on silica gel using DCM / MeOH 97 / 3 as eluent to give intermediate 48 (272 mg, estimated quantitative yield).
[0310] (I-49)
[0311] [ka]
[0312] To a solution of I-48 (256.41 mg, 0.25 mmol) in DCM (3.25 mL) was added TFA (2.92 mL, 38.1 mmol) dropwise at 0° C. After the addition, the reaction mixture was stirred at 25° C. for 15 h. The reaction mixture was diluted with DCM (30 mL) and added dropwise to a cold mixture of NaHCO3 (4268 mg, 50.8 mmol) and water (100 mL). The organic layer was separated and the aqueous layer was extracted with DCM (30 mL, ×1). The combined organic layers were dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel using a gradient DCM / MeOH 96 / 4 as eluent. Pure fractions were collected and evaporated. The residue was co-evaporated with toluene (×2) to give intermediate 49 (180 mg, 92% yield).
[0313] (I-50)
[0314] [ka]
[0315] 1-Propanephosphonic anhydride (757.36 μL, 0.64 mmol) was added dropwise to a stirred solution of I-41 (250 mg, 0.25 mmol), TEA (251.01 μL, 1.81 mmol) and N-methyl-2-morpholinoethanamine (91.75 mg, 0.64 mmol) in DCM (7.53 mL) at 0° C. After addition, the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with dichloromethane and poured into water. The aqueous layer was extracted with DCM. The organic layer was dried over MgSO4 and the solvent was evaporated. The residue was purified by flash column chromatography on silica gel using DCM / MeOH 96 / 4 as eluent to give intermediate 50 (304 mg, estimated quantitative yield).
[0316] (I-51)
[0317] [ka]
[0318] To a solution of I-50 (281.59 mg, 0.25 mmol) in DCM (3.25 mL) was added TFA (2.92 mL, 38.1 mmol) dropwise at 0° C. After addition, the reaction mixture was stirred at 25° C. for 16 h. The reaction mixture was diluted with DCM (30 mL) and added dropwise to a cold mixture of NaHCO3 (4268 mg, 50.8 mmol) and water (100 mL). The organic layer was separated and the aqueous layer was extracted with DCM (×1, 30 mL). The combined organic layers were dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel using a gradient DCM / MeOH 95 / 5 as eluent. Pure fractions were collected and evaporated. The residue was co-evaporated with toluene (×2) to give intermediate 51 (220 mg, estimated quantitative yield).
[0319] (I-52)
[0320] [ka]
[0321] 1-Propanephosphonic anhydride (514.57 μL, 0.43 mmol) was added dropwise to a stirred solution of I-41 (205 mg, 0.21 mmol), TEA (205.83 μL, 1.48 mmol) and morpholine (82.33 mg, 0.95 mmol) in DCM (6.17 mL) at 0° C. After addition, the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with dichloromethane and poured into water. The aqueous layer was extracted with DCM. The organic layer was dried over MgSO4 and the solvent was evaporated. The residue was purified by flash column chromatography on silica gel using DCM / MeOH 98 / 2 as eluent to give intermediate 52 (145 mg, 66% yield).
[0322] (I-53)
[0323] [ka]
[0324] To a solution of I-52 (145 mg, 0.14 mmol) in DCM (1.77 mL) was added TFA (1.58 mL, 20.68 mmol) dropwise at 0° C. After the addition, the reaction mixture was stirred at 10° C. for 16 h. The reaction mixture was diluted with DCM and poured into saturated aqueous NaHCO3 (20 mL). The organic layer was separated and the aqueous layer was extracted with DCM. The combined organic layers were dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel using a gradient DCM / MeOH 98 / 2 as eluent to give intermediate 53 (100 mg, 89% yield).
[0325] (I-54)
[0326] [ka]
[0327] A solution of I-38 (200 mg, 0.37 mmol), I-22 (182.07 mg, 0.37 mmol), glyoxylic acid (54.49 mg, 0.74 mmol) and 3 Å molecular sieves in THF (4.49 mL) was stirred at 50° C. for 5 h. At this stage, MeOH (5 mL) was added and the reaction mixture was stirred at 50° C. for 16 h. The reaction mixture was filtered and the solvent was evaporated under reduced pressure. The residue was purified together with another batch by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-10 μm, 50×150 mm, mobile phase: 0.25% NH4HCO3 in water, MeOH) to give intermediate 54 (100 mg, 22% yield).
[0328] (I-55)
[0329] [ka]
[0330] 1-Propanephosphonic anhydride (254.64 μL, 0.21 mmol) was added dropwise to a stirred solution of I-54 (100 mg, 0.1 mmol), TEA (101.86 μL, 0.73 mmol) and morpholine (40.74 mg, 0.47 mmol) in DCM (3.06 mL) at 0° C. After addition, the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with dichloromethane and poured into water. The aqueous layer was extracted with DCM. The organic layer was dried over MgSO4 and the solvent was evaporated under reduced pressure to give intermediate 55 (120 mg, estimated quantitative yield).
[0331] (I-56)
[0332] [ka]
[0333] To a solution of I-55 (103.75 mg, 0.1 mmol) in DCM (1.28 mL) was added TFA (1.15 mL, 15 mmol) dropwise at 0° C. After addition, the reaction mixture was stirred at 10° C. for 16 h. The reaction mixture was poured cold into a mixture of DCM (30 mL) and saturated aqueous NaHCO3 (20 mL). The organic layer was separated and the aqueous layer was extracted with DCM (30 mL, ×1). The combined organic layers were dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-10 μm, 50 × 150 mm, mobile phase: 0.25% aqueous NH4HCO3, CH3CN) and the product was coevaporated with toluene (×2) to give compound 56 (45 mg, 56% yield).
[0334] Preparation of compounds compound 1
[0335] [ka]
[0336] I-43 (90 mg, 0.105 mmol), [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (11.5 mg, 0.0157 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (48 mg, 0.315 mmol) and dry THF (43 mL) were stirred in a pressure vessel at room temperature. The vessel was charged with 50 bar of CO gas and stirred at 100 °C for 16 h. The reaction mixture was poured into water and extracted with EtOAc. The organic layer was dried over MgSO4 and the solvent was evaporated under reduced pressure. The resulting residue was purified by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-10 μm, 50 × 150 mm, mobile phase: 0.25% NH4HCO3 in water, CH3CN). The resulting product was purified by preparative SFC (stationary phase: Chiralcel Diacel IH 20×250 mm, mobile phase: CO 2 , EtOH+0.4iPrNH 2 ) to give compound 1 (26 mg, 30% yield) as a white solid (isopropylamine salt).
[0337] 1 H NMR(400MHz,クロロホルム-d)δppm1.02(d,J=6.4Hz,3H)1.22(d,J=6.5Hz,3H)1.38( d,J=7.1Hz,4H)1.51-1.77(m,3H)1.80-1.99(m,3H)2.02-2.24(m,4H)2.82(br dd,J=32.5,5.1Hz,5H)3.30-3.38(m,5H)3.41(s,4H)3.50-3.63(m,5H)3.65(s,1H)3.97(br d,J=12.4Hz,3H)4.03-4.19(m,4H)4.61(d,J=8.0Hz,1H)5.78(br s,1H)5.83(br d,J=8.0Hz,1H)6.89(d,J=8.0Hz,1H)7.02(s,1H)7.08(d,J=2.1Hz,1H)7.14(d,J=1 .0Hz,1H)7.17-7.22(m,1H)7.71(d,J=8.5Hz,1H);Rt=2.15min, MS(ESI)m / z757[M+H] + , LCMS method: 1
[0338] Compound 2
[0339]
change
[0340] I-45 (195 mg, 0.225 mmol), [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (16.45 mg, 0.0225 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (102.68 mg, 1.019 g / mL, 0.674 mmol) and dry THF (35 mL) were stirred in a pressure vessel at room temperature. The vessel was charged with 50 bar CO gas and stirred at 100 °C for 16 h. The solvent was evaporated from the reaction mixture under reduced pressure. The resulting residue was purified by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-10 μm, 30 × 150 mm, mobile phase: 0.5% NHOAc in water + 10% CHCN, CHCN). Pure fractions were collected and the solvent was evaporated under reduced pressure. The residue was dissolved in water, basified with NaHCO3, and extracted with DCM. The organic layer was dried over MgSO4, filtered, and the solvent was evaporated under reduced pressure to give compound 2 (55 mg, 32% yield).
[0341] 1 H NMR (400 MHz, chloroform-d) δ ppm 1.02 (d, J = 6.7 Hz, 3H) 1.24-1.40 (m, 3H) 1.43 (d, J = 7.2 Hz, 3H) 1.47-1.83 (m, 9H) 1.86-2.17 (m, 6H) 2.71-2.82 (m, 3H) 2.88 (br d,J=4.5Hz,1H)2.93(s,1H)3.01-3.12(m,1H)3.20-3.41(m,7H)3.44-3. 64(m,1H)3.88-4.05(m,5H)4.12-4.39(m,3H)5.60-5.74(m,1H)5.77-5.9 4(m,1H)6.86-6.97(m,2H)6.99-7.07(m,1H)7.09(d,J=2.3Hz,1H)7.20( dd,J=8.5,2.3Hz,1H)7.65-7.73(m,1H);Rt=2.16min, MS(ESI)m / z767[M+H] + ,LCMS method:1
[0342] compound 3
[0343] [ka]
[0344] I-47 (90 mg, 0.105 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (11.6 mg, 0.0158 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (48 mg, 0.316 mmol) and dry THF (43 mL) were stirred at room temperature in a pressure vessel. The vessel was charged with 50 bar of CO gas and stirred at 100 °C for 16 h. The reaction mixture was poured into water and extracted with EtOAc. The organic layer was dried over MgSO4, filtered and the solvent was removed under reduced pressure. The resulting residue was purified by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-10 μm, 50x150 mm, mobile phase: 0.25% NH4HCO3 in water, CH3CN). The resulting product was purified by preparative SFC (stationary phase: Chiralcel Diacel IH 20×250 mm, mobile phase: CO 2 , EtOH+0.4iPrNH 2 ) to give compound 3 (23 mg, 27% yield) as a white solid (isopropylamine salt).
[0345] 1 H NMR(400MHz,chloroform-d)δppm1.02(d,J=6.6Hz,3H)1.22-1.46(m,7H)1.46-1.75(m,6H)1.76-1.86(m, 1H)1.88-2.00(m,3H)2.01-2.15(m,4H)2.69-2.82(m,3H)2.82-2.99(m,2H)3.02-3.12(m,1H)3.19(br d,J=7.0Hz,1H)3.27-3.49(m,7H)3.93-4.07(m,5H)4.14-4.25(m,2H)4.30(d,J=8.6Hz,1H)5.69(br dd,J=6.9,4.8Hz,1H)5.79-5.91(m,1H)6.92(s,2H)7.00-7.12(m,2H)7.20 (dd,J=8.5,2.0Hz,1H)7.66-7.72(m,1H);Rt=2.15 min, MS(ESI)m / z753[M+H] + ,LCMS method:1
[0346] compound 4
[0347] [ka]
[0348] I-49 (180 mg, 0.234 mmol) was dissolved in anhydrous THF (30 mL) in a COware vessel. After degassing with nitrogen, 1,8-diazabicyclo[5.4.0]undec-7-ene [6674-22-2] (180 μL, 1.019 g / mL, 1.205 mmol) was added, followed by [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) [72287-26-4] (1.8 mg, 0.00246 mmol). The mixture was evacuated and backfilled with CO (×3), then heated at 80° C. for 6 h under approximately 30 bar CO pressure. After cooling to room temperature, the mixture was carefully acidified with 1 M HCl solution until the pH reached approximately 5-6. Water (10 mL) and EtOAc (10 mL) were added. The organic layer was separated, washed with brine (10 mL), dried over MgSO4, and filtered. SiliaMetS DMT (approximately 5 eq.) was then added, and the suspension was stirred at room temperature for 16 h, then filtered through Celite and washed with EtOAc. The filtrate was evaporated under reduced pressure to give the crude product as a yellow solid. The crude product was purified by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-5 μm, 50×250 mm, mobile phase: 0.5% aqueous NHOAc+10% CHCN, CHCN) to give compound 4 (77 mg, 49% yield) as an off-white solid.
[0349] 1H NMR(400MHz,クロロホルム-d)δppm1.01(d,J=6.4Hz,3H)1.42(br d,J=7.0Hz,4H)1.49-1.66(m,2H)1.71(dt,J=11.1,5.7Hz,1H)1.76-1.84(m,1H)1.92(br s,2H)1.99-2.13(m,4H)2.69-2.85(m,3H)2.90(br dd,J=15.0,10.3Hz,1H)2.97(s,3H)3.03-3.12(m,1H)3.22-3.39(m,5H)3.91-4.0 7(m,3H)4.18(d,J=12.3Hz,1H)4.20-4.27(m,1H)4.37(d,J=8.4Hz,1H)5.59-5.76( m,1H)5.85(dd,J=15.6,8.4Hz,1H)6.94(s,1H)6.92-6.96(m,1H)7.02-7.13(m,2H) 7.20(dd,J=8.5,2.3Hz,1H)7.69(d,J=8.6Hz,1H);Rt=2.03 points, MS(ESI)m / z669[M+H] + , LCMS method: 1
[0350] Compound 5
[0351]
change
[0352] I-51 (220 mg, 0.253 mmol) was dissolved in anhydrous THF (30 mL) in a COware vessel. After degassing with nitrogen, 1,8-diazabicyclo[5.4.0]undec-7-ene [6674-22-2] (200 μL, 1.019 g / mL, 1.339 mmol) was added, followed by [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) [72287-26-4] (2 mg, 0.00273 mmol). The mixture was evacuated and backfilled with CO (×3), then heated at 100 °C for 6 h under approximately 30 bar CO pressure. After cooling to room temperature, the mixture was carefully acidified with 1 M HCl solution until the pH reached approximately 5-6. Water (10 mL) and EtOAc (10 mL) were added. The organic layer was extracted, washed with brine (10 mL), dried over MgSO4, and filtered. SiliaMet DMT (approximately 5 equiv.) was then added and the suspension was stirred at room temperature for 16 h before being filtered through Celite and washed with EtOAc. The filtrate was evaporated under reduced pressure to give the crude product as a yellow solid. The crude product was purified by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-5 μm, 50×250 mm, mobile phase: 0.5% aqueous NHOAc+10% CHCN, CHCN) to give the product (98 mg, 50% yield). The product was further purified by flash column chromatography on silica gel using DCM / MeOH (100:0 to 95:5) as eluent to give compound 5 (76 mg, 39% yield) as a white solid.
[0353] 11H NMR (400 MHz, chloroform-d) δ ppm 1.03 (d, J = 6.6 Hz, 3H) 1.43 (d, J = 7.3 Hz, 4H) 1.52 - 1.75 (m, 3H) 1.76 - 1.98 (m, 3H) 1.98 - 2.18 (m, 4H) 2.46 - 2.63 (m, 5H) 2.65 - 2.94 (m, 5H) 2.98 (s, 2H) 3.24 - 3.38 (m, 4H) 3.41 - 3.77 (m, 6H) 3.82 - 4.06 (m, 3H) 4.15 - 4.28 (m, 2H) 4.35 (br d, J = 8.1 Hz, 1H) 5.62 - 5.77 (m, 1H) 5.78 - 5.95 (m, 1H) 6.88 - 7.01 (m, 2H) 7.10 (s, 2H) 7.20 (dd, J = 8.6, 2.2 Hz, 1H) 7.70 (d, J = 8.6 Hz, 1H). (2 / 1 mixture of rotamers visible by NMR); Rt = 2.01 min, MS (ESI) m / z 768 [M+H] + , LCMS method: 1
[0354] Compound 6 and Compound 7
[0355] [Chemical formula]
[0356] I-53 (100 mg, 0.12 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (18.04 mg, 0.025 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (95.34 mg, 0.63 mmol) and dry THF (25.87 mL) were stirred at room temperature in a pressure vessel. The vessel was charged with 50 bar of CO gas and stirred at 100 °C for 16 h. The reaction mixture was cooled to room temperature and the solvent was evaporated under reduced pressure. The residue was purified by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-10 μm, 50 × 150 mm, mobile phase: 0.25% NH4HCO3 in water, MeOH) to give impure compound 6 and impure compound 7. Compound 6 was purified by preparative SFC (stationary phase: Chiralcel Diacel OJ 20×250 mm, mobile phase: CO2, EtOH+0.4iPrNH2) to give pure compound 6 as the isopropylamine salt (3 mg, 3% yield). Compound 7 was purified by preparative SFC (stationary phase: Chiralcel Diacel OJ 20×250 mm, mobile phase: CO2, EtOH+0.4iPrNH2) to give pure compound 7 as the isopropylamine salt (40 mg, 42% yield).
[0357] compound 6 1H NMR(400MHz,クロロホルム-d)δppm0.75-1.01(m,2H)1.13(br d,J=6.5Hz,3H)1.26(br s,3H)1.37(br d,J=7.3Hz,5H)1.54-1.65(m,2H)1.67-1.87(m,4H)1.88-2.04(m,4H)2.13(br s,1H)2.53(br s,1H)2.75-2.90(m,3H)2.95(br s,1H)2.99-3.16(m,1H)3.31(br d,J=14.3Hz,2H)3.35-3.46(m,2H)3.47-3.65(m,4H)3.65-3.86(m,4H)3.88-4.10(m,3H)4.17(br d,J=11.8Hz,1H)5.55(br s,1H)5.90(br s,1H)6.93(br d,J=8.2Hz,1H)7.05-7.12(m,1H)7.13-7.24(m,2H)7.69(br d,J=8.6Hz,2H);Rt=2.04 points, MS(ESI)m / z711[M+H] + , LCMS method: 1
[0358] Compound 7 1H NMR(400MHz,クロロホルム-d)δppm1.03(d,J=6.6Hz,3H)1.21(d,J=6.4Hz, 3H)1.38(d,J=7.0Hz,4H)1.53-1.76(m,3H)1.77-1.96(m,3H)2.00(br s,1H)2.09-2.29(m,3H)2.78(br d,J=4.8Hz,2H)2.88(br d,J=10.1Hz,2H)2.95(br s,1H)3.33(br d,J=14.1Hz,1H)3.38-3.47(m,1H)3.54(br d,J=10.1Hz,1H)3.72(br dd,J=7.6,5.8Hz,6H)3.83(br d,J=12.1Hz,1H)3.90-4.04(m,4H)4.17(d,J=12.3Hz,1H)4.28(d,J=8.1Hz,1H)5.80(br s,1H)5.86(br d,J=7.9Hz,1H)6.90(d,J=8.1Hz,1H)7.04-7.09(m,2H)7.12(d,J=1.3Hz,1H)7. 19(dd,J=8.5,2.3Hz,1H)7.70(d,J=8.4Hz,1H);Rt=2.02 points, MS(ESI)m / z711[M+H] + , LCMS method: 1
[0359] Compound 8 and Compound 9
[0360]
change
[0361] I-56 (45 mg, 0.056 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (8.26 mg, 0.011 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (44.12 mg, 0.29 mmol) and dry THF (11.81 mL) were stirred in a pressure vessel at room temperature. The vessel was charged with 50 bar of CO gas and stirred at 100 °C for 16 h. The solvent was evaporated from the reaction mixture under reduced pressure. The residue was purified by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-10 μm, 50 × 150 mm, mobile phase: 0.25% NH4HCO3 aqueous solution, CH3CN) to give compound 8 (23 mg, 58% yield) and impure compound 9. Compound 9 was further purified by preparative HPLC (stationary phase: RP XBridge Prep C18 OBD-10 μm, 50 × 150 mm, mobile phase: 0.25% NH4HCO3 in water, CH3CN) followed by preparative SFC (stationary phase: Chiralcel Diacel OJ 20 × 250 mm, mobile phase: CO2, EtOH + 0.4iPrNH2) to give pure compound 9 as the isopropylamine salt (3.3 mg, 8% yield).
[0362] compound 8 1 H NMR(400MHz,chloroform-d)δppm 1.03(d,J=6.4Hz,3H)1.34-1.51(m,4H)1.75-1.88(m,1H)1.90-2.23(m,8H)2. 70-2.83(m,2H)3.10-3.31(m,3H)3.44-3.61(m,3H)3.62-3.80(m,8H)3.85(br d,J=15.2Hz,1H)4.03-4.17(m,3H)4.21(br d,J=7.2Hz,1H)5.75(td,J=7.7,3.7Hz,1H)5.98(dd,J=15.5,8.8Hz,1H)6.92-6.96(m,1H)6.99(br d,J=6.7Hz,2H)7.09(d,J=2.2Hz,1H)7.17(dd,J=8.5,2.2Hz,1H)7.68(d,J=8.5Hz,1H);Rt=1.92 min, MS(ESI)m / z697[M+H] + ,LCMS method:2
[0363] compound 9 1 H NMR(400MHz,chloroform-d)δppm 0.88(br s,1H)1.10(br d,J=6.5Hz,3H)1.20-1.33(m,6H)1.35-1.52(m,2H)1.76-1.89(m,2H)1.92-2.11(m,5H)2.19(br s,1H)2.77(br s,3H)3.03(br dd,J=15.0,8.9Hz,1H)3.11-3.26(m,3H)3.37-3.52(m,2H)3.54-3.80(m,8H)3.86(br d,J=15.0Hz,1H)3.99(br d,J=7.5Hz,1H)4.06(s,1H)4.21-4.24(m,1H)5.70(br d,J=15.9Hz,1H)6.08-6.29(m,1H)6.89(br d,J=8.3Hz,1H)7.08(d,J=1.8Hz,1H)7.17(dd,J=8.4,1.7Hz,1H)7.27-7.32(m,1H)7.47(br s,1H)7.70(d,J=8.5Hz,1H);Rt=2.01min, MS(ESI)m / z697[M+H] + ,LCMS method:1
[0364] Analysis method LCMS High performance liquid chromatography (HPLC) measurements were performed using the LC pump, diode-array (DAD) or UV detector and column specified in each method. Additional detectors were included if necessary (see methods table below).
[0365] The flow from the column was delivered to a mass spectrometer (Mass Spectrometer, MS) configured with an atmospheric pressure ion source. It is within the knowledge of one skilled in the art to set tuning parameters (e.g., scan range, dwell time, etc.) to obtain ions that allow identification of the nominal monoisotopic molecular weight (MW) of the compound. Data collection was performed with appropriate software.
[0366] Compounds were identified based on their experimental retention times (Rt ) and ions. Unless otherwise specified in the tables of data, the molecular ions reported are [M+H] + (protonated molecule) and / or [MH] - (deprotonated molecule). If the compound is not directly ionizable, the type of adduct is specified (i.e., [M+NH4] + , [M+HCOO] - etc.). For molecules with multiple isotopic patterns (Br, Cl), the values reported are those obtained for the lowest isotopic mass. All results were obtained with experimental uncertainties typically associated with the methods used.
[0367] Hereinafter, "SQD" means single quadrupole detector, "MSD" means mass selected detector, "RT" means room temperature, "BEH" means crosslinked ethylsiloxane / silica hybrid, "DAD" means diode array detector, and "HSS" means high strength silica.
[0368] LCMS method code (flow rate in mL / min; column temperature (T) in °C; runtime in min)
[0369] [Table 2]
[0370] LCMS results (RT means retention time)
[0371] [Table 3]
[0372] NMR 1 H NMR spectra were recorded on Bruker Avance III and Avance NEO spectrometers. CDCl3 was used as the solvent unless otherwise stated. Chemical shifts are expressed in ppm relative to tetramethylsilane.
[0373] Pharmacological analysis Biological Example 1 Homogeneous time-resolved fluorescence (HTRF) binding assay of terbium-labeled myeloid cell leukemia 1 (Mcl-1) utilizing the BIM BH3 peptide (H2N-(C / Cy5Mal)WIAQELRRIGDEFN-OH) as a binding partner of Mcl-1.
[0374] Apoptosis, or programmed cell death, ensures normal tissue homeostasis, and its dysregulation can lead to several human pathologies, including cancer. The extrinsic apoptotic pathway is initiated through the activation of cell surface receptors, whereas the intrinsic apoptotic pathway occurs at the outer mitochondrial membrane and is governed by binding interactions between pro-apoptotic and anti-apoptotic Bcl-2 family proteins, including Mcl-1. In many cancers, anti-apoptotic Bcl-2 proteins, such as Mcl-1, are upregulated, thus enabling cancer cells to avoid apoptosis. Thus, inhibition of Bcl-2 proteins, such as Mcl-1, can result in apoptosis in cancer cells and provide a method for the treatment of said cancers.
[0375] This assay assessed inhibition of the BH3 domain:Mcl-1 interaction by measuring the displacement of a Cy5-labeled BIM BH3 peptide (H2N-(C / Cy5Mal)WIAQELRRIGDEFN-OH) in an HTRF assay format.
[0376] Assay procedure The following assay and stock buffers were prepared for use in the assay: (a) stock buffer: 10 mM Tris-HCl, pH=7.5 + 150 mM NaCl, filtered, sterilized, and stored at 4° C., and (b) 1× assay buffer, with the following components added to fresh stock buffer: 2 mM dithiothreitol (DTT), 0.0025% Tween-20, 0.1 mg / mL bovine serum albumin (BSA). 1× Tb-Mcl-1 + Cy5 Bim peptide solution was prepared by diluting the protein stock solution using 1× assay buffer (b) to 25 pM Tb-Mcl-1 and 8 nM Cy5Bim peptide.
[0377] Using an acoustic ECHO, 100nL of 100x test compound was dispensed into individual wells of a white 384-well Perkin Elmer Proxiplate for a final compound concentration of 1x and a final DMSO concentration of 1%. Inhibitor controls and neutral controls (NC, 100nL of 100% DMSO) were stamped into columns 23 and 24 of the assay plate, respectively. 10μL of 1X Tb-Mcl-1+Cy5 Bim peptide solution was then dispensed into each well of the plate. The plate was centrifuged at 1000rpm for 1 minute using a cover plate and incubated at room temperature for 60 minutes with the plate covered.
[0378] The TR-FRET signal was read on a BMG PHERAStar FSX microplate reader at room temperature using the HTRF optical module (HTRF: excitation: 337 nm, light source: laser, emission A: 665 nm, emission B: 620 nm, integration start: 60 μs, integration time: 400 μs).
[0379] 4. Data Analysis Fluorescence intensities were measured at two emission wavelengths, 665 nm and 620 nm, using a BMG PHERAStar FSX microplate reader, and reported as relative fluorescence units (RFU) for both emissions, as well as the ratio of emissions (665 nm / 620 nm). *The RFU values were normalized to percent inhibition as follows: Inhibition %=(((NC-IC)-(compound-IC)) / (NC-IC))×100 Where IC (inhibitor control, low signal) = average signal of 1X Tb-MCl-1 + Cy5 Bim peptide + inhibitor control, or 100% inhibition of Mcl-1, NC (neutral control, high signal) = average signal with DMSO only 1X Tb-MCl-1 + Cy5 Bim peptide, or 0% inhibition
[0380] Generate an 11-point dose-response curve and calculate the IC based on the following formula: 50 Values (using GenData) were determined. Y=Bottom+(Top-Bottom) / (1+10^((logIC 50 -X) × Hill gradient) where Y = % inhibition in the presence of X inhibitor concentration, Top = 100% inhibition derived from IC (mean signal of Mcl-1 + inhibitor control), Bottom = 0% inhibition derived from NC (mean signal of Mcl-1 + DMSO), Hill slope = Hill coefficient, and IC 50 = Concentration of compound with 50% inhibition relative to Top / neutral control (NC). K i =IC 50 / (1+[L] / K d ) In this assay, [L] = 8 nM and K d =10nM
[0381] Following the procedures described above, representative compounds of the present invention were tested and the results are listed in the table below (nd means not determined).
[0382] [Table 4]
[0383] Biological Example 2 MCL-1 is a regulator of apoptosis and is highly overexpressed in tumor cells that evade cell death. The assay evaluates the cellular potency of small molecule compounds that target regulators of the apoptosis pathway, primarily MCL-1, Bfl-1, Bcl-2, and other proteins of the Bcl-2 family. Protein-protein inhibitors that disrupt the interaction of anti-apoptotic regulators with BH3 domain proteins initiate apoptosis.
[0384] The Caspase-Glo® 3 / 7 assay is a luminescent assay that measures caspase-3 and -7 activity in purified enzyme preparations or in adherent or suspension cell cultures. The assay provides a proluminescent caspase-3 / 7 substrate containing the tetrapeptide sequence DEVD. This substrate is cleaved to release aminociferin, a substrate for luciferase that is used to generate light. Addition of a single Caspase-Glo® 3 / 7 reagent in an "add-mix-measure" format results in cell lysis followed by caspase cleavage of the substrate and generation of a "glow-type" luminescent signal.
[0385] This assay uses the MOLP-8 human multiple myeloma cell line, which is sensitive to MCL-1 inhibition.
[0386] material: Perkin Elmer Envision Multi-droplet 384 and small volume dispensing cassettes Centrifuge ●Countess Automated Cell Counter ●Countess Hemocytometer Slide Assay plate: ProxiPlate-384 Plus, white 384 shallow well microplate ●Duct tape: Topseal A plus ●T175 culture flask
[0387] [Table 5]
[0388] Cell culture medium:
[0389] [Table 6]
[0390] Cell culture: Cell cultures were cultured at 0.2–2.0 × 10 6 The cells were maintained at 100x the cells / mL. The cells were harvested by collecting in a 50 mL conical tube. The cells were then pelleted at 500 g for 5 min, after which the supernatant was removed and resuspended in fresh pre-warmed culture medium. The cells were counted and diluted as necessary.
[0391] Caspase-Glo Reagent: The assay reagent was prepared by transferring the buffer to the substrate vial and mixing. The solution could be stored at 4° C. for up to 1 week with negligible loss of signal.
[0392] Assay procedure: Compounds were delivered in assay compatible plates (Proxiplates) and stored at -20°C.
[0393] The assay always includes one reference compound plate containing the reference compound. The plate was spotted with 40 nL of compound (0.5% DMSO final in cells, serial dilution, 30 μM top concentration 1 / 3 dilution, 10 doses, duplicates). Compounds were used at room temperature and 4 μL of pre-warmed medium was added to all wells except columns 2 and 23. Negative controls were prepared by adding 1% DMSO to the medium. Positive controls were prepared by adding the appropriate positive control compound to the medium at a final concentration of 60 μM. The plate was prepared by adding 4 μL of negative control to column 23, 4 μL of positive control to column 2, and 4 μL of cell suspension to all wells in the plate. The plate with cells was then incubated at 37° C. for 2 minutes. The assay signal reagent was the Caspase-Glo solution described above and 8 μL was added to all wells. The plate was then sealed and measured after 30 minutes.
[0394] The activity of the test compounds was calculated as the percentage change in apoptosis induction as follows:
[0395] [Table 7] Effect%(AC 50 )=100-((Sample-LC) / (HC-LC)) * 100 % Control = (Sample / HC) * 100 Control %min = ((Sample-LC) / (HC-LC)) x 100
[0396] Table: AC measured for representative compounds of formula (I) 50 The average value is reported across all runs for all batches of a particular compound.
[0397] [Table 8]
Claims
1. Formula (I) 【Chemistry 1】 [In the formula, R 1a and R 1b are each independently Hydrogen, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, C 3~7 Cycloalkenyl, Het 1 , Ar 1 , Het 2 , and Cy 1 is selected from the group consisting of Said C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, or C 3~7 Cycloalkenyl optionally has one or two R 2 or Or R 1a and R 1b together with the N atom to which it is attached form a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, wherein the S atom is substituted to S(=O) or S(=O) 2 wherein each heterocyclyl is optionally independently selected from oxo, OR f , S.R. f , N.R. d R e , CN, Halo, CF 3 , and optionally, OR f , S.R. f , CN, and halo; 1~4 substituted with one or two substituents selected from the group consisting of alkyl; Or R 1a and R 1b together with the N atom to which it is attached form a 6-11 membered bicyclic fully saturated heterocyclyl containing one N atom and optionally one or two additional heteroatoms each independently selected from O, S, and N, wherein the S atom is substituted to S(=O) or S(=O) 2 wherein each heterocyclyl is optionally independently selected from oxo, OR f , S.R. f , N.R. d R e , CN, Halo, CF 3 , and optionally, OR f , S.R. f , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Each R 2 is OR f , S.R. f , CN, Halo, CF 3 , N.R. m R n , S.O. 2 R c , C(=O)R c , C(=O)OR d , C(=O)NR d R e , S.O. 2 N.R. d R e , C 3~7 Cycloalkyl, C 3~7 Cycloalkenyl, Het 1 , Ar 1 , Het 2 , and Cy 1 are independently selected from the group consisting of Said C 3~7 Cycloalkyl or C 3~7 Cycloalkenyl is optionally represented by OR f , S.R. f , CN, Halo, and NR d R e and is substituted with one or two substituents each independently selected from the group consisting of: R c is C 1~6 Alkyl, C 3~7 Cycloalkyl, Het 1 , Ar 1 , and Het 2 is selected from the group consisting of R m and R n are each independently hydrogen, methyl, C 2~7 Alkyl, C 3~7 Cycloalkyl, Het 1 , Ar 1 , and Het 2 wherein C is selected from the group consisting of 2~7 Alkyl or C 3~7 Cycloalkyl is optionally selected from the group consisting of: OR i , S.R. i , N.R. g R h , CN, halo, and optionally, OR i , S.R. i , C.N., N.R. g R h and C substituted with one substituent selected from the group consisting of halo. 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; R d and R e are each independently hydrogen, methyl, C 2~7 Alkyl, C 3~7 Cycloalkyl, Het 1 , Ar 1 , and Het 2 wherein C is selected from the group consisting of 2~7 Alkyl or C 3~7 Cycloalkyl is optionally selected from the group consisting of: OR i , S.R. i , N.R. g R h , CN, halo, and optionally, OR i , S.R. i , C.N., N.R. g R h and C substituted with one substituent selected from the group consisting of halo. 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Or R d and R e together with the N atom to which it is attached form a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, wherein the S atom is substituted to S(=O) or S(=O) 2 wherein each heterocyclyl may optionally be independently selected from the group consisting of OR i , S.R. i , N.R. g R h , CN, Halo, CF 3 , and optionally, OR i , S.R. i , CN, and halo; 1~4 substituted with one or two substituents selected from the group consisting of alkyl; Or R d and R e together with the N atom to which it is attached form a fused 6-11 membered bicyclic fully saturated heterocyclyl containing one N atom and optionally one or two additional heteroatoms each independently selected from O, S, and N, wherein the S atom is substituted to S(=O) or S(=O) 2 wherein each heterocyclyl may optionally be independently selected from the group consisting of OR i , S.R. i , N.R. g R h , CN, Halo, CF 3 , and optionally, OR i , S.R. i , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; n is 1 or 2; R f is hydrogen, C 1~6 Alkyl, CF 3 , C 3~7 Cycloalkyl, Het 1 , Ar 1 , Het 2 wherein C is selected from the group consisting of 1~6 Alkyl or C 3~7 Cycloalkyl is optionally represented by OR i , S.R. i , CN, Haro, NR m R n , S.O. 2 R c , C(=O)R c , C(=O)OR d , C(=O)NR d R e , S.O. 2 N.R. d R e , C 3~7 Cycloalkyl, Het 1 , Ar 1 and Het 2 is substituted with one substituent selected from the group consisting of R g and R h are each independently hydrogen, C 1~6 Alkyl, and C 3~7 cycloalkyl; Or R g and R h together with the N atom to which it is attached form a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, wherein the S atom is substituted to S(=O) or S(=O) 2 may be formed, Het 1 each independently represents a 4- to 7-membered monocyclic fully saturated heterocyclyl containing 1 or 2 heteroatoms selected from O, S, and N, wherein the S atom is substituted to S(=O) or S(=O) 2 wherein each heterocyclyl may optionally be independently selected from the group consisting of OR i , S.R. i , N.R. j R k , CN, Halo, CF 3 , and optionally, OR i , S.R. i , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Het 2 each independently represents a 5-6 membered monocyclic aromatic ring containing 1, 2, 3, or 4 heteroatoms selected from O, S, and N, wherein the S atom is substituted to S(=O) or S(=O) 2 wherein each of said aromatic rings may optionally be independently selected from the group consisting of OR i , S.R. i , N.R. j R k , CN, Halo, CF 3 , and optionally, OR i , S.R. i , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Cy 1 represents a 6-11 membered bicyclic fully saturated ring system optionally containing 1 or 2 heteroatoms each independently selected from O, S, and N, wherein the S atom is substituted to S(=O) or S(=O) 2 wherein said ring systems may optionally each independently form OR i , S.R. i , N.R. j R k , CN, Halo, CF 3 , and optionally, OR i , S.R. i , CN, and halo; 1~4 substituted with 1 or 2 substituents selected from the group consisting of alkyl; Ar 1 are optionally each independently: OR i , S.R. i , N.R. g R h , CN, Halo, CF 3 , and optionally, OR i , S.R. i , CN, and halo; 1~4 represents phenyl substituted by one or two substituents selected from the group consisting of alkyl, R i is hydrogen, C 1~6 Alkyl, or C 3~7 represents cycloalkyl, R j and R k are each independently hydrogen, C 1~6 Alkyl, and C 3~7 cycloalkyl; R 3 is hydrogen, C 1~4 Alkyl, or C 1~4 represents alkyl-OH, R 4 represents hydrogen or methyl; R 5 is -(C=O)-phenyl, -(C=O)-Het 4 or -(C=O)-Het 3 wherein the phenyl, Het 3 , or Het 4 is optionally substituted with 1 or 2 substituents selected from methyl or methoxy; Het 4 each independently represents a C-linked 4- to 7-membered monocyclic fully saturated heterocyclyl containing 1 or 2 heteroatoms selected from O, S, and N, the S atom being substituted to S(=O) or S(=O) 2 may be formed, Het 3 represents a C-linked 5- or 6-membered monocyclic aromatic ring containing 1, 2, or 3 heteroatoms each independently selected from O, S, and N; Y is O or CH 2 represents X 1 is CR 6 represents X 2 is CR 7 represents X 3 is CR 8 represents R 6 , R 7 , and R 8 each independently represents hydrogen, fluoro, or chloro; X 4 is O or NR 5 Represents or a pharma- ceutically acceptable salt or solvate thereof.
2. R 1a and R 1b is one or two R 2 C optionally substituted with 1~6 represents an alkyl group, Or R 1a and R 1b are taken together with the N atom to which they are attached to form a 4-7 membered monocyclic fully saturated heterocyclyl containing one N atom and optionally one additional heteroatom selected from O, S, and N, wherein the S atom is substituted to S(=O) or S(=O) 2 may be formed, Each R 2 is OR f and Het 1 are independently selected from the group consisting of n is 1 or 2; R f is C 1~6 represents an alkyl group, Het 1 each independently represents a 4- to 7-membered monocyclic fully saturated heterocyclyl containing one or two heteroatoms selected from O, S, and N, wherein the S atom is substituted to S(=O) or S(=O) 2 may be formed, R 3 represents hydrogen, R 4 represents methyl, Y is CH 2 represents X 1 is CR 6 represents X 2 is CR 7 represents X 3 is CR 8 represents R 6 , R 7 , and R 8 represents hydrogen, X 4 The compound of claim 1 , wherein represents O.
3. R 3 The compound of claim 1 , wherein represents hydrogen.
4. R 4 The compound of claim 1 , wherein represents methyl.
5. R 4 represents methyl, X 4 The compound of claim 1 , wherein represents O.
6. Y is CH 2 2. The compound according to claim 1 , wherein
7. A compound according to any one of claims 1 to 6, wherein n represents 2.
8. A compound according to any one of claims 1 to 6, wherein n represents 1.
9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 and a pharma- ceutically acceptable carrier or diluent.
10. A process for preparing a pharmaceutical composition according to claim 9, comprising mixing a pharma- ceutically acceptable carrier with a therapeutically effective amount of a compound according to any one of claims 1 to 8.
11. A compound according to any one of claims 1 to 8 or a pharmaceutical composition according to claim 9 for use as a medicament.
12. A compound according to any one of claims 1 to 8 or a pharmaceutical composition according to claim 9 for use in the prevention or treatment of cancer.
13. 13. The compound or pharmaceutical composition for use according to claim 12, wherein the cancer is selected from prostate cancer, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, B-cell chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
14. A method for treating or preventing cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 8 or a pharmaceutical composition according to claim 9.
